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ABSTRACT 
The homeodomain transcription factor CDX2 is a key player in intestinal 
differentiation. Therefore, it is not surprising to find its expression significantly altered in 
carcinogenic processes of the gastrointestinal tract. In the stomach, de novo CDX2 
expression drives a preneoplastic lesion known as intestinal metaplasia that increases 
the risk of gastric cancer development. Quite the opposite, in the context of 
colorectal cancer, CDX2 has been classically described as a tumour-suppressor, 
although this view has been gradually challenged in the last few years. 
Notwithstanding, it is known that tumours retaining CDX2 expression are more 
differentiated and show better outcome in terms of survival. Thus, a comprehensive 
understanding of CDX2 regulation stands out as a research priority, for in the long-
run, the acquired knowledge could be integrated into alternative therapeutic 
strategies that might benefit the patient. Taking into consideration that the 
extracellular microenvironment is also important to the cellular malignant behavior 
as genetic constrains, we decided to tackle its influence over CDX2 expression in two 
fronts:, analyze the possible role of DNA epigenetic changes, hypothesizing that 
infection by Helicobacter pylori and the generation of chronic inflammation could in 
some way affect the CDX2 gene methylation pattern and induce its transcription; 
and in a more exploratory approach, establish 3D culture models that better mimic 
the in vivo milieu, hypothesizing that they would provide new insights regarding 
signaling pathways affecting CDX2 levels. We show here that there is a lack of 
correlation between CDX2 methylation status and its expression in intestinal 
metaplasia and gastric cancer cell lines, excluding this mechanism as a CDX2 
regulatory feature during gastric malignancy. On the other hand, through genome-
wide screening of the 3D culture system, comprising a gastric cancer cell line with 
CDX2 expression and the basement matrix matrigel, we were able to identify the 
RNA-binding protein MEX3A as putatively involved in CDX2 regulation. Further 
supported by an evolutionary functional link to its Caenorhabditis elegans 
orthologue MEX-3, we demonstrate that MEX3A maintains a conserved repressive 
function over CDX2 in gastric and intestinal cellular models. This is dependent on the 
interaction with a specific binding determinant present in CDX2 mRNA 
3`untranslated region. Moreover, MEX3A overexpression carries phenotypic 
consequences, impairing intestinal differentiation and cellular polarization, while 
promoting gain of stemness properties. As a result, we describe for the first time a 
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mechanism of CDX2 post-transcriptional control, likely contributing to intestinal 
homeostasis and carcinogenesis, and add a new layer to the already intricate CDX2 
regulatory network. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESUMO 
O factor de transcrição homeobox CDX2 é um elemento crítico na diferenciação 
intestinal. Assim, não é inesperado o facto de apresentar níveis de expressão 
significativamente alterados em processos carcinogénicos do tracto gastrointestinal. 
No estômago, a expressão de novo de CDX2 induz uma lesão pré-neoplásica 
denominada metaplasia intestinal que confere um risco acrescido de 
desenvolvimento de carcinoma gástrico. Pelo contrário, no contexto colorectal, 
este gene tem sido geralmente descrito como um supressor tumoral, embora esta 
classificação tenha vindo a ser posta em causa nos últimos anos. Mesmo assim, 
reconhece-se que tumores com expressão de CDX2 são mais diferenciados e 
detêm melhor prognóstico em termos de sobrevida. Torna-se, então, fundamental 
obter uma compreensão aprofundada dos processos de regulação de CDX2, pois a 
longo prazo o conhecimento adquirido pode ser integrado em estratégias 
terapêuticas alternativas que poderão beneficiar o paciente. Tendo em 
consideração que o microambiente extracelular é, tal como as alterações 
genéticas, importante para o comportamento celular maligno, decidimos 
confrontar a sua influência sobre a expressão de CDX2 em duas partes: analisar o 
possível papel de alterações epigenéticas ao nível do promotor do gene, 
colocando a hipótese de que o processo de infecção por Helicobacter pylori e a 
subsequente resposta inflamatória poderão criar condições que afectam o perfil de 
metilação de CDX2 induzindo a sua transcrição; e numa abordagem de carácter 
mais exploratório, estabelecer modelos de cultura 3D que mimetizem o ambiente in 
vivo, colocando a hipótese de que estes permitiriam obter novos dados no que 
respeita às vias de sinalização que afectam os níveis de CDX2. Demonstrámos que 
não existe uma correlação entre o estado de metilação do promotor de CDX2 e a 
sua expressão na metaplasia e em linhas celulares de cancro gástrico, excluindo 
este mecanismo de regulação no processo de carcinogénese gástrica. Por outro 
lado, através de um varrimento transcricional do sistema de cultura 3D, constituído 
por uma linha celular gástrica e a matriz de membrana basal matrigel, identificámos 
uma proteína de ligação ao ARN designada MEX3A como estando potencialmente 
envolvida na regulação de CDX2. Apoiados numa base funcional evolutiva em 
relação ao papel do ortólogo MEX-3 em Caenorhabditis elegans, provámos que o 
MEX3A mantém uma função conservada enquanto repressor da expressão de 
CDX2 em modelos celulares gástricos e intestinais. Este efeito é dependente da 
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interacção com um motivo de ligação específico presente na região 3` não-
traduzida do ARN mensageiro de CDX2. Adicionalmente, a sobrexpresão de 
MEX3A acarreta consequências fenotípicas, afectando a diferenciação intestinal e 
polaridade celular, promovendo simultaneamente o ganho de propriedades 
estaminais. Em conclusão, descrevemos pela primeira vez um mecanismo pós-
transcricional de controlo de CDX2, com relevância para a homeostasia intestinal e 
provavelmente carcinogénese, adicionando um novo elemento à complexa rede 
de regulação do gene CDX2. 
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General introduction and aims 
Chapter 1 
 1  
  
Gastrointestinal (GI) cancers are a leading cause of morbidity worldwide. 
Given the high number of affected patients, a tremendous amount of effort has 
been spent in the search to prevent and treat these diseases over the past decades. 
This section intends to summarize specific aspects of GI carcinogenesis, as the gastric 
and intestinal settings constitute the biological frame upon which this work was 
developed.  
 
 
1.1.1  An overview on gastric cancer 
Gastric cancer is currently the fourth most common cancer worldwide, as 8% of 
newly diagnosed cases are stomach malignancies (Ferlay et al. 2010). Its frequency 
varies greatly across different geographic locations, being Eastern Asia, Eastern 
Europe, and South America the areas with highest incidence. In spite of a steady 
decline over the past decades, more than 700.000 people still perish each year, 
making it the second leading cause for cancer-related deaths. In Portugal, it places 
fifth and third in terms of incidence and mortality, respectively (IARC 2010).  
About 90 to 95% of malignant tumours of the stomach are epithelial in origin 
and classified as adenocarcinomas. According to the Lauren system, two major 
histological types can be described with distinct clinicopathological features: diffuse 
and intestinal (Lauren 1965). Diffuse-type cancers consist of poorly-cohesive cells 
diffusely infiltrating the gastric wall, with little or no gland formation. They occur more 
often in low-risk areas, prevalently in young and female patients, being associated 
with worse prognosis (Bosman et al. 2010). Intestinal-type cancers show recognizable 
gland formation that is similar in microscopic appearance to the intestinal mucosa, 
growing in an expanding, rather than an infiltrative pattern. It is more common in 
countries with high incidence rates, mainly in male and older patients, but its 
frequency is decreasing (de Vries et al. 2007).   
The marked incidence variation observed according to geographic location 
and socio-economic status, even within the same country, demonstrates that a 
complex interplay between genetic variation and environmental exposures 
constitutes the basis for gastric cancer susceptibility. Whereas about 10% present 
familial aggregation, which includes hereditary diffuse gastric cancer, an autosomal-
dominant syndrome associated with E-cadherin (CDH1) gene germline mutations 
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 1.1  GASTROINTESTINAL CARCINOGENESIS 
(Guilford et al. 1998), most gastric cancers occur sporadically. A heterogeneous 
genetic and epigenetic milieu with incremented activity of oncogenes, such as 
ERBB2 amplification, inactivation of tumour suppressor genes like TP53, deregulation 
of signalling pathways like TGF-β, and microsatellite instability (MSI), has been 
observed in the context of gastric malignancies (Zheng et al. 2004a). Furthermore, it 
is evident that DNA polymorphisms for inflammatory cytokine genes like IL1B, along 
with individual immune function contribute to the disease (El-Omar et al. 2000). 
Epidemiological data also suggests that dietary and behavioural elements are 
determinant in gastric cancer aetiology. The most relevant risk factors include high 
salt intake, sustained cigarette smoking, and heavy alcohol consumption, while the 
intake of fruits and vegetables is probably protective (Guggenheim and Shah 2013). 
Nonetheless, the most important advance in gastric adenocarcinoma epidemiology 
was its association with Helicobacter pylori infection, culminating in the classification 
of the gram-negative bacterium as a type I carcinogen by the International Agency 
for Research on Cancer (IARC 1994), and on the recognition of the carcinogenic 
propensity different strains harbour. For example, the presence of virulence factors 
encoded by the cag 
pathogenicity island genes, 
such as CagA, are 
characteristic of strains 
carrying higher risk (Yamaoka 
2010). Pelayo Correa`s 
groundwork defined a series  
of histological stages in the 
canonical progression to 
gastric adenocarcinoma that 
still stands today (Correa 
1992). According to the 
pathway, bacterial infection 
and the previously mentioned 
constrains trigger a prolonged 
precancerous process that 
evolves sequentially through 
increasingly more severe 
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lesions: chronic gastritis, multifocal atrophy, intestinal metaplasia (IM) and dysplasia. 
This multistage process transforms the normal gastric epithelium, ultimately leading to 
intestinal-type gastric cancer (Figure 1). Although H. pylori significantly increases the 
risk of developing both subtypes of gastric cancer, the diffuse-type typically 
progresses following chronic inflammation with no known precursor lesion, though 
silencing of CDH1 gene is a key carcinogenic event.  
H. pylori is estimated to infect close to half of the world`s population, making it 
the most widespread infection in the planet. Colonization of the human stomach 
can occur in early childhood, particularly in developing countries, and persists 
lifelong. In countries like Japan and Portugal, the prevalence of infection remains 
very high, reaching about 80% of the population. IM arises in approximately 30% of 
the infected individuals, from which only about 7% will progress to cancer (Uemura et 
al. 2001). Notwithstanding, the five-year survival rate for gastric cancer ranges from 
10 to 30% (Dicken et al. 2005), since it is a largely asymptomatic disease at early 
stages. Therefore, it is often detected late, when already in advanced progression. 
Treatment modalities have been improving slowly and are currently limited, involving 
surgical resection, together with adjuvant and palliative chemotherapy-or 
radiotherapy-based regimens (Selgrad et al. 2010). The role of H. pylori eradication 
as the main preventive strategy continues to be controversial and largely 
dependent on the degree and extent of preneoplastic changes at the time of 
eradication (de Vries et al. 2007). New approaches for prevention and management 
are thus necessary, and early detection of gastric preneoplastic lesions stands in the 
front line as one of the most appealing strategies to ameliorate prognosis and 
increase survival. 
 
 
1.1.2  Intestinal metaplasia 
IM has been extensively studied as a putative preneoplastic lesion, and 
evidence of a clear association with stomach cancer development exists. An 
epidemiological study has demonstrated that IM is related with a six-fold increased 
comparative risk of malignancy and that 83% of gastric carcinomas arise in this 
setting (Uemura et al. 2001). This suggests a direct causal relationship, further 
supported by Mongolian gerbil rodent experimental models (Watanabe et al. 1998; 
Zheng et al. 2004b). The question of IM reversibility is crucial for clinical purposes, and 
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although conflicting, existing data points towards little evidence in its favour upon 
eradication of H. pylori, particularly under infection with high virulence strains (Barros 
et al. 2010), which makes the understanding of this lesion pathophysiology an even 
more imperative matter. 
Metaplasias are general processes of cell- and tissue-type transformations 
(Slack 2007). These constitute fascinating phenomena, in the sense that they appear 
to disrupt our traditional conception of development as being hierarchically 
determined. Gastric IM is a prototype of glandular to glandular metaplasia and can 
be described as a multifocal cellular shift in the normal gastric gene expression 
background towards an intestinal-oriented genetic program, leading to the 
appearance of biochemically well-defined intestinal cell-types, alone or 
intermingled with gastric cells. As stomach and intestine arise from neighbouring 
territories of the endoderm during normal embryogenesis, IM presumably reflects this 
close developmental relationship. Nevertheless, it implies that certain embryological 
rulings must be circumvented or even erased upon specific microenvironmental 
stimuli (Tosh and Slack 2002). 
There are conflicting theories regarding the starting point of this lesion. Some 
authors support the hypothesis of a transdifferentiation process, the switch of a 
differentiated gastric cell to a fully mature intestinal cell, eventually involving de(re)-
differentiation steps (Kirchner et al. 2001; Goldenring et al. 2011). Assuming the 
transformed cells have inherent characteristics of an adult phenotype, with an 
already restricted lifespan, the biggest caveat in this theory is that these cell types 
may not survive long enough for the necessary epithelial self-renewal and 
maintenance demanded in the persistence of a continuous, though abnormal, 
regeneration process. So, most studies rely upon the hypothesis that IM is initiated by 
a new commitment pathway at the level of stem cells. The consensual view 
considers endogenous tissue-specific stem cells as being involved. The gastric 
epithelium is organized into numerous gastric units composed of flask-shaped tubular 
glands, several of which feed into a single pit that opens out onto the surface 
epithelium lined with mucous-secreting cells. Glands are constituted by various cell 
types located within three distinct regions denoted by the isthmus, neck, and base. 
Multipotent gastric stem or progenitor cells have been described to be located in 
the isthmus or base region, giving rise to all differentiated cells via complex migration 
patterns; consequently, gastric glands are monoclonal. Alternatively, other authors 
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propose that bone marrow-derived cells might be the initiator cells in the gastric 
carcinogenic process, including IM and dysplasia, by homing in and engrafting to 
the injury sites (Houghton et al. 2004; Varon et al. 2012). Although enticing as a 
theory, there has been limited translation of this model into the human setting. 
Whichever the case, IM is most probably the outcome of an adaptive response that 
goes amiss, in which the tissue tries to cope with several aggressive inputs, but ends 
up with the creation of susceptible ground for neoplastic transformation (Mesquita et 
al. 2006). 
In terms of classification, two major gastric IM types can be recognized,             
taking into account not only morphological, but also molecular alterations, like loss 
and gain of mucinous differentiation markers and mucin-associated 
carbohydrate antigens (Reis et al. 1999; Silva et al. 2002). The complete IM or 
intestinal type (previously denominated type I) reflects a complete switch in the 
differentiation program, with loss of gastric mucins MUC1, MUC5AC, and MUC6, and 
de novo expression of the intestinal mucin MUC2. It is characterized by the presence 
of absorptive cells, Paneth cells and goblet cells secreting sialomucins, similar to the 
small intestinal phenotype. The incomplete IM or GI-mixed type reflects a mixture of 
gastric and intestinal components, both at the glandular and cellular level (Niwa et 
al. 2005). It is characterized by the presence of columnar and goblet cells secreting 
sialomucins and/or sulphomucins (previously denominated types II and III, 
respectively), similar to the colonic phenotype. Remarkably, the ectopic intestinal 
glands still preserve a normal cell migration pattern, which is achieved by a 
redeployment of the proliferative niche from the middle to the base of the gland 
(Inada et al. 2001; Sakamoto et al. 2011). Reciprocal interactions between the 
epithelium and the mesenchyme might be behind this architectural remodelling 
(Mutoh et al. 2005a), as the induction of a mesenchymal intestinal phenotype during 
the early stages of IM might lead to the establishment of a positive regulatory loop 
involving paracrine signals (Sakagami et al. 1984). It is not yet clear if the two IM 
types can be considered sequential steps in a shared process of gradual 
intestinalization or if they arise independently. The possibility exists that the 
incomplete type is biologically more unstable as it reflects an aberrant differentiation 
program without phenotypic parallel in the adult organism. In agreement, 
epidemiological data, though scarce, shows that it confers increased risk of gastric 
cancer development compared to the complete type (Filipe and Jass 1986; Rokkas 
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et al. 1991; Filipe et al. 1994), highlighting the importance of stratification concerning 
prognostic significance (González et al. 2013). Curiously, bacterial colonization is 
typically absent in foci of complete IM (Bravo and Correa 1999), favouring a 
presumably protective function. 
 
 
1.1.3  Colorectal carcinogenesis 
Colorectal cancer (CRC) is currently the third most common cancer worldwide, 
as 10% of the newly diagnosed cases are malignancies of the colon or rectum. 
Almost 60% of the cases occur in developed regions and the areas with highest 
incidence are North America, Australia/New Zealand and Europe (Ferlay et al. 2010). 
More than 600.000 people die each year, making it the fourth leading cause for 
cancer-related death. In Portugal, considering the total number of cases, it places 
first in terms of incidence and mortality (IARC 2010). As for the small intestine, it has 
a remarkably low incidence of primary carcinomas, especially considering its length 
and surface area, and those that do occur are often related to hereditary 
syndromes. 
About 90% of sporadic tumours occur in individuals over the age of fifty. Other 
risk factors include family history, a diet low in ﬁbers and high in red meat, alcohol, 
smoking, and sedentary occupation (Johnson et al. 2013). A present estimate is that 
15-30% of CRCs have a familial component. Less than 5% of these happen in a 
recognizable setting of highly penetrant cancer syndromes due to germline 
mutations, being the most common the hereditary nonpolyposis CRC and familial 
adenomatous polyposis (Fearon 2011). Despite advances in surgical techniques and 
adjuvant therapy, there has been only a modest improvement in survival for patients 
with advanced neoplasms (Edwards et al. 2012). Hence, effective primary and 
secondary preventive approaches must be developed to reduce morbidity and 
mortality.  
Since the description of the classic adenoma-carcinoma pathway (Fearon and 
Vogelstein 1990), defining CRC as the result of a gradual accumulation of changes 
that transform normal glandular epithelial cells into adenoma, followed by invasive 
carcinoma and eventually metastatic cancer, our understanding of its molecular 
pathogenesis has advanced and led to numerous revisions of this linear tumour 
progression model. It is now recognized that loss of genomic stability is a hallmark 
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feature of colorectal carcinogenesis (Grady and Carethers 2008), and this property 
led to the establishment of a classification system: (i) the chromosomal instability 
(CIN) phenotype, found in as many as 85% of tumours and defined by the presence 
of aneuploidy or structural aberrations; (ii) the MSI phenotype, defined by the 
presence of unstable loci due to inactivation of genes in the DNA mismatch repair 
family; and (iii) the CpG island methylator phenotype, exhibiting both global DNA 
hypomethylation and hypermethylation of gene promoters that contain CpG islands  
(Pritchard and Grady 2011). It is the accumulation of mutations combined with 
multiple cycles of clonal selection that results in the deregulation of signalling 
pathways controlling cell proliferation, differentiation, apoptosis, angiogenesis and 
invasion, ultimately culminating in cancer development. 
 
 
1.1.4  Intestinal homeostasis 
The intestinal tract is anatomically divided into two well-defined segments, the    
small intestine and large intestine (or colon), lined by a specialized single layer of 
cells organized into two morphologically and functionally distinct compartments: 
flask-shaped submucosal invaginations known as crypts of Lieberkühn, and finger-
shaped luminal protrusions termed villi, which dramatically increase the absorptive 
surface area of the small intestine. The crypt constitutes the proliferative 
compartment of the intestinal epithelium; it is monoclonal and maintained by four to 
six multipotent stem cells located in the lower third (Bjerknes and Cheng 1999) that 
give rise to intermediate descendants referred to as transit-amplifying cells. The villus 
represents the differentiated compartment and is polyclonal as its cells derive from 
several crypts (Potten and Loeffler 1990). Absorptive enterocytes, mucous-producing 
goblet cells, and hormone-secreting enteroendocrine cells migrate upwards along 
the basement membrane to the epithelium apex, where they undergo apoptosis, 
being subsequently exfoliated into the intestinal lumen (Hall et al. 1994). Paneth cells 
are unusual in that they settle at the crypt base and are the only cell type migrating 
downwards (Bry et al. 1994). The modular organization of the small intestine and 
colon is globally comparable. Histologically, there are, however, two important 
differences between them. The colon carries no villi; instead, it has a flat surface 
epithelium and larger colonic crypts extending deep into the submucosa. The 
relative abundance of each of the main cell types also varies markedly within the 
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different intestinal segments. Enterocytes are highly polarized cells responsible for 
absorbing and transporting nutrients across the epithelium, secreting a cocktail of 
hydrolytic enzymes into the gut. They make up more than 80% of all intestinal 
epithelial cells. Goblet cells secrete protective mucins and trefoil proteins required for 
the movement and effective removal of luminal contents, while providing protection 
against shear stress and chemical damage. Accordingly, their numbers increase 
from the proximal (4%) to distal (16%) intestine (Karam 1999). Enteroendocrine cells 
coordinate gut physiology through specific hormone production (Höcker and 
Wiedenmann 1998). They are scattered as individual cells throughout the mucosa, 
representing a small proportion (<1%) of the cells lining the epithelium (Schonhoff et 
al. 2004). Finally, Paneth cells have a function in innate immunity, synthesizing 
bactericidal agents such as defensins and lysozyme (Porter et al. 2002). They are 
absent from the colon and have a life expectancy of six to eight weeks (van der Flier 
and Clevers 2009), much longer than that of their terminally differentiated villus 
counterparts, with a turnover rate of roughly three to five days (Wright and Irwin 
1982).  
Currently, some controversy exists as to the presence of distinct types of 
intestinal stem cells. The “+4 position” model assumes the crypt base is exclusively 
populated by terminally differentiated Paneth cells and that stem cells are located 
just above them,  on average at the +4 position (Potten et al. 1974). These cells 
were shown to divide once every day and to be unusually sensitive to radiation, 
possibly preventing the accumulation of deleterious genomic changes (Potten 
1977). They were described to retain DNA labelling, and are also called label-
retaining cells (LRCs), a feature suggested as being the result of asymmetric strand 
segregation (Potten et al. 2002). The “stem cell zone” model states that small, 
undifferentiated, cycling cells called crypt base columnar (CBC) cells, residing in a 
stem cell-permissive environment and wedged between the Paneth cells at the base 
of the crypts, are likely to be the true stem cells (Cheng and Leblond 1974; Bjerknes 
and Cheng 1999). Yet, definitive proof of stemness requires putative stem cells to be 
experimentally linked to their progeny, and this has proven elusive due to lack of 
specific markers (Barker et al. 2012). The musashi-1 (MSI1) gene encodes a RNA-
binding protein initially described as a regulator of asymmetric division in neural stem 
cells (Glazer et al. 2012). Later studies showed that it denotes multipotent stem cells 
in other settings, being also highly expressed at the crypt base, with expression  
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evident  on  the  CBC  cells,  as  well  as  in  some  LRCs  (Potten et al. 2003). However, 
its broad expression domain suggests that it is a marker of early committed 
progenitors alike. Lineage tracing techniques in inducible mouse models led to the 
identification of the leucine rich repeat-containing G-protein coupled receptor 5 
(LGR5), the first specific CBC cell marker (Barker et al. 2007). The LGR5 protein acts as 
the receptor for a small family of Wnt agonists called R-spondins. Lgr5+ cells are highly 
uniform in morphology, invariably touch Paneth cells, and divide each day. Another 
robust marker of Lgr5+ stem cells called olfactomedin-4 (OLFM4) has recently 
emerged. It is a member of the olfactomedin domain-containing family and 
encodes a secreted glycoprotein that appears to have anti-apoptotic and cell 
cycle regulatory characteristics (Grover et al. 2010). Molecular in situ hybridization 
revealed that OLFM4 is highly expressed in normal CBC cells in human small intestine 
and colon (van der Flier et al. 2009). The most reliable candidate as an LRC marker 
to date is BMI1, which encodes a component of the polycomb repressing complex 1 
that acts as a chromatin modifier, being implicated in the stable maintenance of 
gene repression (Valk-Lingbeek et al. 2004). It has attracted attention due to its role 
in regulating self-renewal of neural and hematopoietic progenitors. Bmi1 was found 
to mark rare cells at the +4 cell position uniquely in about 10% of the proximal small 
intestine (Sangiorgi and Capecchi 2008). 
Modelling of the intestinal epithelium is based on a delicate balance between 
self-renewal and differentiation, which must be maintained throughout life. 
Noteworthy, in all species studied, the crypt-villus axis junction represents the 
physical threshold from which intestinal cells acquire their final functional 
characteristics, arguing for conserved molecular mechanisms involved in this 
process. In fact, intestinal homeostasis is dependent on autocrine and paracrine 
interactions between the mucosa and the underlying mesenchyme, and many of 
the intervening signalling pathways, such as Wnt, Bone Morphogenetic Protein 
(BMP), and Notch, have been identified (Crosnier et al. 2006). These molecular 
signals provide some of the basic principles through which intestinal architecture is 
organized, but it is still not clear at what point stem cell progeny loses its potency and 
becomes irreversibly committed to differentiation. Irrespectively of how this occurs, 
cell fate decisions need to be closely timed in relation to the pattern of cell divisions. 
While the mechanisms controlling intestinal cell transitions are far from completely 
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understood, it is obvious that they involve transcription factors conferring 
compartment-specific gene expression. 
 
 
 
 
 
  
When considering the molecular basis of intestinal differentiation, a common 
point of convergence exists, independently of the biological setting – the caudal 
(cad) type homeobox 2 gene (CDX2). This transcription factor is exclusively present in 
the intestine and de novo expressed in every foci of ectopic intestinal differentiation 
in the body, associated with carcinogenic processes. Its embryonic requirement and 
transcriptional activity over intestine-specific genes incorporate the properties of a 
“master regulator”. 
 
 
1.2.1  CDX2 homeobox gene and its targets 
One of the earliest isolated homeobox genes in Drosophila showed for the first 
time maternal as well as zygotic expression, accumulating in a concentration 
gradient spanning the antero-posterior axis of the embryo. During later 
embryogenesis, it was expressed in more posterior structures, therefore it was named 
cad (Mlodzik et al. 1985). Soon after, three murine orthologues designated Cdx1 
(Duprey et al. 1988), Cdx2 (James and Kazenwadel 1991) and Cdx4 (Gamer and 
Wright 1993) were characterized. With the exception of Cdx4, they are confined to 
the posterior gut endoderm during later development and the mature intestine after 
birth.  
The human CDX2 gene was independently cloned from an adult jejunal   
cDNA library (Drummond et al. 1997) and by differential screening of mRNA from 
CRC (Mallo et al. 1997). It maps to the ParaHox gene cluster in chromosome 13q12.3, 
has three exons and encodes a 313 amino acid protein containing a nuclear 
translocation and activation domain in the amino terminus (Trinh et al. 1999), and a 
highly conserved helix-turn-helix DNA-binding motif called the homeodomain 
towards the carboxyl terminus. The CDX2 homeodomain shares 100% homology with 
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 1.2  THE INTESTINAL TRANSCRIPTION FACTOR CDX2 
 
the hamster CDX3 homeodomain, 96% with the mouse CDX2, and even 88% with the 
homeodomain from Drosophila Cad, implying recognition of similar DNA targets. 
CDX proteins have been demonstrated to bind as a monomer or dimer to one or 
more CDX-responsive elements, typically consisting of the consensus sequence 
(A/C)TTTAT(A/G), in direct or reverse orientation both in promoter and gene 
enhancer regions (Margalit et al. 1993; Taylor et al. 1997; Verzi et al. 2010). These 
motifs are frequently juxtaposing (Troelsen et al. 1997) or even intersecting (Lambert 
et al. 1996) a TATA-box sequence, usually part of the RNA polymerase II binding site.  
Although some reports demonstrate that CDX2 can act as an indirect repressor, 
counteracting CDX1 or other transcription factor-mediated activation, by 
competing for the same binding sites (Gautier-Stein et al. 2003; Furumiya et al. 2013) 
or through interaction with basal components of the transcriptional machinery (Chun 
et al. 2007; Mutoh et al. 2010), most studies provide strong evidence of a role in 
activating gene transcription (Verzi et al. 2011). Indeed, CDX2 is determinant for the 
expression of numerous intestinal differentiation markers, and it has been shown to 
regulate absorptive lineage-specific factors such as sucrase-isomaltase (Suh et al. 
1994; Boudreau et al. 2002), lactase phlorizin hydrolase (Troelsen et al. 1997; Fang et 
al. 2000), carbonic anhydrase 1 (Drummond et al. 1996), guanylyl cyclase C (Park et 
al. 2000), calbindin-D9K (Lambert et al. 1996; Wang et al. 2004a), liver-intestine 
cadherin (Hinoi et al. 2002), and villin (Yamamichi et al. 2009); goblet cell-specific 
factors such as MUC2 (Mesquita et al. 2003; Yamamoto et al. 2003)  and  trefoil 
factor 3 (Shimada et al. 2007);  and enteroendocrine cell-specific proglucagon (Jin 
and Drucker 1996). On the contrary, CDX2 levels consistently seem lowest in Paneth 
cells, a lineage recently shown to be suppressed by CDX2 overexpression-mediated 
loss of nuclear β-catenin (Crissey et al. 2011). CDX2 is also involved in controlling the 
expression of additional molecules that contribute to cellular dynamics, including 
processes of proliferation (Uesaka et al. 2002), growth arrest (Bai et al. 2003; Aoki et 
al. 2011), migration (Coskun et al. 2010), adhesion (Lorentz et al. 1997; Sakaguchi et 
al. 2002; Hinkel et al. 2012), metabolism and transport (Modica et al. 2009; Kakizaki et 
al. 2010), inflammation (Wang et al. 2005), glycoproteome modulation (Isshiki et 
al. 2003), and apoptosis (Mallo et al. 1998). In any case, regulatory outcome 
ultimately results from the cooperative balance with other important transcription 
factors, being mostly relevant the hepatocyte nuclear factor (HNF1 and HNF4) and 
GATA-binding factor (GATA4/5/6) families (Boudreau et al. 2002; Verzi et al. 2010; 
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Verzi et al. 2013). On the other hand, these and other transcription factors, such as 
KLF4, can be directly regulated by CDX2 (Mahatan et al. 1999; Boyd et al. 2010). 
Hence, the complex hierarchies of control that govern gene expression during 
intestinal differentiation and development are determined by the stoichiometry of 
different transcription factors and cofactors within intestinal cells at any given time, 
as well as by the type, number, and arrangement of cis-acting elements in the 
regulatory regions of intestinal genes. 
 
 
1.2.2  Role in homeostasis  
During embryogenesis, CDX homologues participate in patterning of the 
vertebral column (Subramanian et al. 1995; Chawengsaksophak et al. 1997; van Nes 
et al. 2006), as well as in haematopoiesis (Wang et al. 2008), via HOX gene regulation 
and with a certain degree of functional redundancy (van den Akker et al. 2002; 
Savory et al. 2009). Both Cdx1 and Cdx2 are expressed during endoderm 
development and in adult intestine; however, the specific role of each member and 
the extent of their functional equivalence is still not completely understood. In the 
later embryo, CDX1 and CDX2 levels vary quantitatively along the rostrocaudal axis, 
with highest expression of CDX1 in the distal portion of the colon and highest CDX2 
expression in the proximal colon, diminishing in either direction (James et al. 1994; 
Silberg et al. 2000). A fairly complementary gradient of expression has also been 
described along the vertical crypt-villus axis, with the former primarily localized to the 
crypt, and the latter primarily along the villus, although with less staining towards the 
tip (Silberg et al. 1997; Rings et al. 2001; Kim et al. 2002; Silberg et al. 2002). These 
patterns endure throughout the lifespan of the animal and are also observed in 
human tissue (Walters et al. 1997; Boulanger et al. 2005). They are thought to reflect 
intrinsically different functionalities, with CDX1 associated to a more proliferative 
phenotype and CDX2 to a more differentiated one, conceding a partially 
interchangeable activity in certain contexts (Verzi et al. 2011). Cdx1−/− mutants are 
viable and fertile, and like transgenics overexpressing Cdx1, display no overt 
intestinal phenotype (Subramanian et al. 1995; Bonhomme et al. 2008; Crissey et al. 
2008). Cdx2 precedes and is needed for Cdx1 onset during intestinal development 
(Eda et al. 2002; Silberg et al. 2002; Mutoh et al. 2009), and Cdx1 requirement is 
only unmasked upon Cdx2 loss, as their combined absence in the adult stage 
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significantly enhances lethality effects of isolated Cdx2 deficiency (Verzi et al. 2010; 
Verzi et al. 2011; Stringer et al. 2012). It therefore follows that CDX2 function in the 
adult intestine is more vital than that of CDX1. 
The role of CDX2 started to be established in vitro, when it was observed that 
forced expression in the undifferentiated intestinal cell line IEC-6 arrests proliferation 
and initializes an epithelial polarity program (Suh and Traber 1996). Cdx2-/- mice 
embryos display pre-implantation lethality and die in utero between embryonic day 
3.5 and 5.5, whereas the Cdx2+/- mutants are viable, but exhibit skeletal anomalies or 
stunted growth (Chawengsaksophak et al. 1997; Tamai et al. 1999). Crucial evidence 
that CDX2 functions in specifying intestinal cell fate was initially obtained by 
observing that 90% of the heterozygous mice develop multiple polyps within the first 
three months of life, particularly in the proximal colon. These polyps present the 
remaining Cdx2 allele inactivated and reveal a homeotic reversion towards anterior 
differentiation (Beck et al. 1999). This process of intercalary regeneration means that 
local sporadic Cdx2 haploinsufficiency conveys a signal for a pathway of rostral 
phenotype; hence, a gradient of positional information is observed, with areas of 
stratified squamous epithelium similar to that seen in the oesophagus, areas 
resembling the gastric mucosa, and even areas reminiscent of the small intestine. 
Wild-type male hosts with Cdx2–/– cells from mutant female donors also develop 
chimaeric intestinal patches of organotypically normal stomach epithelium (Beck et 
al. 2003). Of interest, the underlying host stroma concurrently assumes a gastric 
phenotype, proving that endodermal expression of CDX2 initiates 
endodermal/mesodermal cross-talk and is the primary signal for gut differentiation, 
subsequently involving appropriate feedback loops (Stringer et al. 2008). A 
complementary approach, relying in transgenic expression of Cdx2 in the stomach, 
demonstrated that CDX2 is sufficient to induce intestinal enterocytes with enzymatic 
and absorptive functions in vivo (Mutoh et al. 2005b). This is reinforced by these mice 
being able to survive over one month after extensive small bowel resection, when 
compared to the short seven day lifespan of surgery-controls. 
Other animal models have been independently reported, in which embryonic 
lethality of Cdx2 ablation was circumvented by conditionally targeting its knockout 
at posterior developmental stages. Pending on temporal restrictions, this inactivation 
differentially impacts global intestinal morphology. Early loss results in anterior 
transformation of the small intestine to an oesophageal phenotype (Gao et al. 2009), 
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whereas in latter induction the intestine shows a more gastric-like identity, with 
impaired endo-lysosomal trafficking and inefficient segregation of apico-basal 
membrane domains (Gao and Kaestner 2010; Grainger et al. 2010). Conditional 
inactivation in the already adult mice compromises enterocyte function, causing 
severe malnutrition and death in about three weeks (Verzi et al. 2010; Verzi et al. 
2011). A limited ablation strategy compatible with long-term survival has been 
applied in this setting revealing the presence of partial gastric-nature metaplasias 
associated with loss of all differentiated intestinal cell types (Hryniuk et al. 2012; 
Stringer et al. 2012). Hence, CDX2 stands out as being the most critical element in the 
development, differentiation, and maintenance of the intestinal phenotype.  
 
 
1.2.3  Involvement in carcinogenesis 
Beyond its homeotic function, CDX2 is also involved in processes of 
leukemogenesis (Lengerke and Daley 2012) and GI carcinogenesis. Conflicting data 
regarding the nature of CDX2 function in tumour initiation and development exist, 
and most probably CDX2 assumes different roles in dissimilar contexts.   
 
IM and gastric cancer 
An association between IM and intestinal-type gastric carcinoma has been 
previously established (Correa 1992). It is now widely recognized that the main 
molecular driver of this preneoplastic condition is de novo expression of CDX2. 
Several studies have described the presence of both CDX1 and CDX2 in nearly all 
gastric IM foci (Bai et al. 2002; Almeida et al. 2003; Kim et al. 2006; Barros et al. 2008). 
But proof of concept supporting CDX2 involvement in this process was provided by 
two transgenic mouse models achieving inappropriate Cdx2 expression in the gastric 
epithelium. These mice develop IM, characterized by the presence of absorptive, 
goblet, and enteroendocrine cell-types (Mutoh et al. 2002; Silberg et al. 2002). One 
model even progressed to gastric cancer after long-term induction (Mutoh et al. 
2004), reinforcing the implication of IM in the genesis of gastric carcinoma. Besides 
being ectopically expressed in IM, it has been repeatedly demonstrated that CDX2 
expression is downregulated in the progression from IM to gastric cancer (about 50% 
are positive), and that CDX2 positivity significantly correlates with a more 
differentiated (intestinal) histology and better prognosis (Kaimaktchiev et al. 2004; 
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Mizoshita et al. 2004; Liu et al. 2007a). Nevertheless, intestinal differentiation markers 
are not exclusive to intestinal-type gastric cancer and the diffuse-type can also 
have features of intestinal differentiation (Almeida et al. 2003).  
The spectrum of IM in the human body is broader. Accordingly, CDX2 has been 
shown to be present in abnormal foci of intestinal differentiation in the oesophagus, 
liver, gallbladder and pancreas (Barros et al. 2012). These metaplasias also bear 
clinical significance. For example, CDX2 is ectopically expressed in Barrett’s 
oesophagus, a precancerous condition that develops from mucosal injury incurred 
after chronic gastroesophageal acid and bile reflux, harbouring an increased risk of 
oesophageal adenocarcinoma development (Eda et al. 2003; Groisman et al. 2004; 
Yousef et al. 2008). Aberrant expression of CDX2 is also detected in IM of the 
gallbladder, a lesion associated with cholelithiasis, dysplasia, and carcinoma (Wu et 
al. 2005; Sakamoto et al. 2007). 
 
Colorectal cancer 
The role of CDX2 protein during CRC development remains controversial, as 
different studies suggest both negative and positive modulation of tumourigenesis. In 
this regard, Cdx2+/- heterozygous mice develop polyp-like lesions characterized by 
gastric heteroplasia in the colon, as described above (Chawengsaksophak et al. 
1997; Beck et al. 1999; Tamai et al. 1999). These are more sensitive to azoxymethane-
induced colonic adenocarcinoma than wild-type mice (Bonhomme et al. 2003). 
Similarly, it was shown that the colonic polyp number is about six times higher in 
Apc+/∆716 Cdx2+/- compound mutant mice compared to heterozygous Apc+/- 
littermates, which mainly develop adenomatous polyposis of the small intestine (Aoki 
et al. 2003). CDX2 expression has also been reported to be markedly reduced at 
later stages of human colorectal carcinogenesis (Mallo et al. 1997), particularly in 
high grade dysplasia and during adenocarcinoma invasion (Ee et al. 1995). 
Furthermore, exogenous CDX2 expression in human colon cancer cell lines induces a 
less malignant phenotype, inhibiting proliferation and invasion, while promoting the 
expression of genes characteristic of mature intestinal cells (Suh and Traber 1996; 
Mallo et al. 1998; Gross et al. 2008). Together, the above findings suggest that CDX2 
functions as a putative tumour-suppressor and this has been the prevailing paradigm 
in this context. Conversely, CDX2 expression seems to be heterogeneously lost at the 
invasive tumour edge (Brabletz et al. 2004) and only reduced in a subset of CRCs, 
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particularly those with minimal differentiation (Hinoi et al. 2001; Hinoi et al. 2003). In 
agreement, loss of chromosome 13 has been seldom observed in CRCs and CDX2 
sequence mutations are exceedingly rare, only occurring in repeat sites of MSI+ 
cancers (Wicking et al. 1998; da Costa et al. 1999; Woodford-Richens et al. 2001; 
Subtil et al. 2007). It was also reported that CDX2 overexpression in colon cancer cell 
lines can induce anchorage-independent growth and migration (Uesaka et al. 2002; 
Dang et al. 2006; Chun et al. 2007). Moreover, immunohistochemical analysis has 
commonly detected strong CDX2 expression in more than 80% of human colon 
cancer samples (Moskaluk et al. 2003; Werling et al. 2003; Kaimaktchiev et al. 2004; 
Witek et al. 2005). Recently, recurrent 13q12 chromosomal amplifications targeting 
the CDX2 locus were described in CRCs (Salari et al. 2012). It was demonstrated that 
colorectal-derived tumours and cell lines with amplification exhibit CDX2 
dependency concerning cell survival and proliferation, leading to its classification as 
a lineage-survival oncogene.   
 
 
1.2.4  CDX2 regulatory network 
The low rate of CDX2 genomic alterations supports the notion that regulation, 
as opposed to structural mutation, accounts for altered CDX2 levels and 
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consequently, for maintaining its normal expression pattern and function under 
homeostasis. Indeed, several transcriptional, post-transcriptional and post-
translational mechanisms have been described to control CDX2, making this a highly 
complex and tightly organized regulatory system (Figure 2). 
 
Transcriptional regulation 
The distinct Cdx2 expression patterns observed embryonically and during 
postnatal life seem to be driven by different genomic fragments. Indeed, the Cdx2 
promoter contains intestine-specific regulatory elements that interact with and 
respond to combinations of different transcription factors integrated within particular 
signalling pathways.  
 
Wnt/β-catenin pathway 
The Wnt pathway plays a crucial role in demarcating the intestinal as opposed 
to gastric fate in the embryonic endoderm, as assessed by the expression of intestinal 
and gastric genes (Kim et al. 2005). A synergistic effect over the Cdx2 promoter is 
obtained with HNF4α and GATA6 expression, which is enhanced by the presence of 
TCF4 and β-catenin (Benahmed et al. 2008). The relevance of this combination is 
underlined by being able to activate ectopic CDX2 expression in non-intestinal HeLa 
cells. However, the effect of the Wnt pathway is intricate, because besides its 
stimulatory role during development, it indirectly downregulates CDX2 via the 
intestine crypt transcription factor SOX9 (Blache et al. 2004). In contrast, CDX2 mRNA 
expression was found to be upregulated by APC (da Costa et al. 1999), which in turn 
can be induced by CDX2 (Lorentz et al. 1997; Olsen et al. 2013). This  inhibits  cell  
proliferation,  probably by disrupting the β-catenin/TCF protein complex and its 
transcriptional activity (Guo et al. 2010). These studies argue for the existence of 
positive and negative feedback loops between the Wnt/β-catenin pathway and 
CDX2, whose aftermath may depend upon the cellular and tissue context.  
 
BMP pathway 
In line with the crucial role of BMPs in intestinal differentiation, and with the 
demonstration that there is an influx of BMP2- and BMP4-producing inflammatory 
cells to the stomach upon H. pylori infection (Bleuming et al. 2006), the BMP pathway 
was shown to be active in gastric IM (Barros et al. 2008). BMP4 was also found in the 
stromal tissue underlying inflamed oesophageal squamous epithelium and Barrett’s 
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metaplasia (Milano et al. 2007). In addition, BMP4 treatment of human primary 
cultured oesophageal cells was reported to induce columnar intestinal-type 
differentiation, accompanied by de novo CDX2 expression, which might be relevant 
for the development of Barrett’s oesophagus (Zhou et al. 2009). Another natural 
occurring model supporting the role of this pathway in CDX2 regulation was 
provided by the observation that loss of BMP activity in juvenile polyps correlates 
with loss of intestinal differentiation and the appearance of gastric metaplasia 
(Barros et al. 2009b). Helicobacter spp. infection was recently shown to upregulate 
the BMP pathway in the gastric context, concomitantly mediating CDX2 increased 
and SOX2 decreased expression (Camilo et al. 2012). In the human digestive tract, 
SOX2 shows an inversely correlated expression pattern to CDX2, decreasing and 
gradually disappearing as IM progresses from the incomplete to the complete type, 
making it a putative gastric differentiation factor (Tsukamoto et al. 2004; Asonuma et 
al. 2009). Accordingly, SOX2 was shown to counteract the effect of HNF4α and 
GATA6 over the activation of the Cdx2 promoter (Benahmed et al. 2008). 
 
Ras/MAPK pathway 
Elevated ERK1/2 activities stimulate S phase entry of intestinal cells and promote 
proliferation in response to mitogenic stimulation (Aliaga et al. 1999). Conversely, low 
sustained levels of the same pathway act as a convergent signal towards G1 arrest 
and intestinal differentiation (Taupin and Podolsky 1999). Accordingly, activation of 
ERK1/2 by oncogenic RAS in human colonic cancer cells modifies the JUN/FOS 
balance favouring a FOS negative effect over the Cdx2 promoter (Lorentz et al. 
1999; Krueger et al. 2009).  
 
PI3K/AKT pathway 
PTEN-mediated tumour suppressive function is invariably linked to PI3K signalling 
inhibition, and it is not surprising to find PTEN decreased expression concomitant with 
inappropriate activation of PI3K pathway as one of the most frequently observed 
features in many human cancers, including colorectal (Zhang et al. 2011). It was 
shown that PTEN induces Cdx2 expression by inhibiting the PI3K/AKT pathway, via 
differential binding activity of the p50 and p65 NF-κB subunits at the Cdx2 promoter, 
with preferential allocation of the p50/p50 homodimer (Kim et al. 2002). PTEN activity 
also promotes intestinal differentiation of gastric cancer cells by increasing CDX2 
expression (Semba et al. 2009). The expression levels of CDX2 are significantly 
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decreased and inversely correlated with the expression pattern of TNF-α during 
active stages of inflammatory bowel disease and in a mouse model of dextran 
sulphate sodium-induced colitis (Coskun et al. 2012). Treating human colon cancer 
cells with TNF-α, an activator of the PI3K signalling pathway, has a contrary effect to 
the one described for PTEN, by preferentially stimulating the DNA binding activity of 
the NF-κB p65/p50 heterodimer at the Cdx2 promoter, decreasing its expression and 
transcriptional activity (Kim et al. 2002). 
 
Autoregulation 
The observation that Cdx2+/- mice do not express the remaining wild-type allele 
in developing intestinal polyps, without evidence for loss of heterozygosity, led to 
postulate that Cdx2 expression could be regulated, in part, by a self-regulatory 
mechanism. The first hints on this possibility were provided by transactivation assays 
performed in pancreatic and intestinal cell lines showing that CDX2 could positively 
regulate its expression in a cell type-specific manner (da Costa et al. 1999; Xu et al. 
1999). These results were confirmed and further extended in relevant biological 
settings provided by the mouse intestine and human IM, where CDX2 was shown to 
bind to its own promoter, which in the latter case, might have an impact in the 
stability of the phenotype and carcinogenic progression (Barros et al. 2011).  
 
Epigenetic modifications 
Methylation is a biochemical modification that consists in the addition of a 
methyl group to cytosine residues predominantly, but not exclusively, at CpG 
dinucleotides enriched within so-called CpG islands. These often overlap functional 
elements, for example, gene promoter regions. It has been shown that exposure to 
acid and/or biliary salts may activate CDX2 expression in human oesophageal 
epithelial cells through promoter demethylation (Liu et al. 2007b). Dietary habits 
could be an important factor determining the methylation status and expression 
levels of CDX2 in gastric carcinogenesis, as epidemiological studies in gastric cancer 
patients established an inverse correlation between CDX2 methylation and selective 
lifestyle factors, like green tea and vegetable intake (Yuasa et al. 2005; Yuasa et al. 
2009). Aberrant CDX2 methylation was frequently observed in CRCs (Kawai et al. 
2005), although other study reported that this was a rare event and described it as a 
unique property of squamous oesophageal cancer cells (Guo et al. 2007). DNA 
methylation and histone modifications associated with CDX1 and CDX2 promoters 
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were also analysed in two human colon cancer cell lines and reported to be 
heterogeneous, but at least for CDX2, differential expression was not due to 
methylation (Lu et al. 2008).  
 
Other environmental influences 
In the setting of gastric carcinogenesis, H. pylori infection is undoubtedly 
considered a major starting point for malignancy. In this regard, several studies 
showed isolated cells or foci of reduced CDX2 expression, mainly in the antral 
gastric epithelium, without any histological evidence of IM in chronic H. pylori 
infected individuals (Satoh et al. 2002; Bornschein et al. 2009). This pattern of 
expression was referred to as “positive staining of single cells” and considered an 
early, albeit still reversible indication of the gastric mucosa intestinalization, strongly 
related with H. pylori infection and gastritis (Vauhkonen et al. 2008). Ensuing, H. pylori 
infection was shown to directly exert a positive regulatory effect over CDX2 in gastric 
cancer cell lines (Matsuda et al. 2008; Barros et al. 2009a). Helicobacter spp. 
infection can also focally induce de novo CDX2 expression in the stomach of mice, 
in a context of mild inflammation and without signs of morphological changes 
resembling IM (Camilo et al. 2012). Nevertheless, the underlying molecular 
mechanisms linking H. pylori presence and CDX2 expression have just started to be 
revealed, and the BMP/SMAD pathway seems to be a determinant mediator of the 
bacteria-induced alterations in the gastric epithelial gene expression program.  
In the oesophageal context, chronic exposure of murine keratinocytes to either 
acid (Marchetti et al. 2003) or bile acids (Kazumori et al. 2006) was shown to induce 
Cdx2 transcription, an effect also confirmed in human oesophageal epithelial cells 
by acid/bile salts combinatorial treatment (Debruyne et al. 2006; Zhou et al. 2009; 
Huo et al. 2010). Since Barrett`s development is clinically associated with 
gastroesophageal reflux and inflammatory cell infiltration, stable changes in the pH 
balance might constitute a key trigger in the early pathological intestinal 
differentiation process of oesophageal cells. Curiously, in gastric metaplasia of the 
duodenum, a lesion characterized by the inverse transformation process of intestinal 
epithelial cells into gastric foveolar cells, as a result of increased gastric acid load, 
transcription of Cdx2 and its intestinal-target genes is impaired (Faller et al. 2004). 
These studies point to the role of the chemical microenvironment as a preponderant 
factor involved in the regulation of tissue-specific gene expression programs. 
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As for the influence of stromal elements, it was observed early on that epithelial-
mesenchymal cellular interactions can differentially affect the expression of CDX1 
and CDX2 homeobox genes (Duluc et al. 1997). For example, different components 
of the basement membrane matrix, which lie at the interface of and are synthesized 
by epithelial and mesenchymal cells, such as Laminin-α1, can positively modulate 
CDX2 expression (Lorentz et al. 1997). A stimulation of CDX2 expression by 
subepithelial colonic myofibroblasts was also reported, mediated by the non-
canonical Wnt family member WNT5A and the epithelial receptor ROR2, contributing 
to inhibition of the canonical Wnt signalling and intestinal differentiation (Pacheco 
and Macleod 2008). On the other hand, collagen type I induces phenotypic 
changes in CRC cells through the β1-integrin/FAK signalling pathway that involve 
reduced Cdx2 promoter activity and mRNA expression (Brabletz et al. 2004). In 
agreement with this, a model of orthotopic and heterotopic xenografs in nude mice 
demonstrated that CDX2 expression is adaptable and strongly dependent on the 
microenvironment (Benahmed et al. 2007).  
 
Post-transcriptional regulation by microRNAs 
Due to the absence of CDX2 expression in about half of the gastric cancer 
cases and heterogeneous loss in CRCs, it was hypothesized that microRNAs (miRs) 
could also be associated with CDX2 silencing in these contexts. Computational 
prediction of miR-binding sites, using independent databases, led to the selection of 
miR-9 and miR-204 as putative candidates for CDX2 regulation (Rotkrua et al. 2011). 
A comparative analysis of CDX2 and miR-9 expression in a panel of gastric cancer 
tissues revealed an overall inverse correlation between both, and in vitro 
experimental data, confirmed that miR-9 interacts directly and specifically with the 
CDX2 3`untranslated region (UTR), leading to downregulation of CDX2 target genes 
and promotion of cell growth. More recently, it was demonstrated that exogenous 
CDX1-induced expression of miR-9, miR-16 and miR-22 suppresses CDX2 mRNA by 
targeting its 3`UTR in a CRC cell line (Tagawa et al. 2012).  
 
Post-translational regulation 
Phosphorylated forms of p38 MAPKs were shown to be mostly retained in the 
nuclei of villus cells, with differential p38α kinase activity constituting an early and 
necessary event for the initiation of the intestinal differentiation program (Houde et 
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al. 2001). This stimulatory effect is accomplished by CDX2 phosphorylation, 
enhancing its transcriptional ability without involvement in the loss of proliferative 
potential or cell survival. On the other hand, phosphorylation by ERK1/2 MAPKs of 
serine 60 within the amino-terminal activation domain of CDX2, reduces its 
transcriptional capability and impairs certain intestinal differentiation properties 
(Rings et al. 2001; Lemieux et al. 2011). This modification was mainly found in the 
proliferating compartment of the intestine, while the nonphosphorylated and more 
active CDX2 was predominantly found in the differentiated region, in agreement 
with the localization of pERK1/2 (Aliaga et al. 1999). In addition, activation of the 
ERK1/2 MAPK cascade was shown to promote ubiquitin-proteasome-dependent 
turnover of the CDX2 protein (Krueger et al. 2009). Two independent studies have 
elucidated how CDX2 regulation can be coordinated with the cell cycle machinery. 
It was observed that CDX2 undergoes CRM1-dependent nuclear export and 
subsequent proteolytic degradation by interaction with CDK2 in proliferative 
intestinal cells (Boulanger et al. 2005). The CDK2-mediated phosphorylation of CDX2 
was found to occur downstream of the homeodomain at serine 283, identified as 
being part of a conserved motif of four evenly spaced serines called the 4S motif, 
similar to the one controlling β-catenin degradation by the proteasome (Gross et al. 
2005). Preventing phosphorylation through this site blocked polyubiquitination and 
stabilized CDX2, with impact on overall cell behaviour. In conclusion, CDX2 contains 
multiple phosphorylation sites that either positively or negatively balance its activity 
and/or stability in response to different signalling pathways, being conceivable that 
their combined action is required for the onset of the complete differentiation 
process. 
 
 
 
 
 
  
Presently, it is well established that gene expression is regulated at multiple 
levels, as previously demonstrated for CDX2, and that the diverse processes involved 
are integrated within each other. Transcriptional control is one of the most important 
steps within the gene regulation cascade. Nevertheless, the significance of post-
 23 
 1.3  POST-TRANSCRIPTIONAL REGULATION OF GENE EXPRESSION 
 
CHAPTER 1.  GENERAL INTRODUCTION AND AIMS 
transcriptional control is evolving, as the ability to reprogram protein synthesis is a 
common theme in embryonic development, wound healing, inflammation, 
metabolic stress and aging. An overview of the main concepts of post-transcriptional 
regulation is presented, focusing on RNA-binding proteins (RBPs) and their roles in 
development and disease. 
 
 
1.3.1  From transcripts to proteins 
An increasing number of publications show that a poor correlation between 
steady-state transcript abundances and corresponding protein pools generally exists 
in almost every organism (de Sousa Abreu et al. 2009; Maier et al. 2009; Vogel et al. 
2010). In accordance, a recent study comprehensively analysed mRNA and protein 
levels, half-lives, transcription and translation rate constants for thousands of genes in 
NIH3T3 mouse fibroblasts, and found that mRNA levels only explain around 40% of the 
variability in protein levels (Schwanhäusser et al. 2011). Whether this exact 
percentage is valid for other cell types is unknown. Thus, it is clear that a significant 
fraction of Eukaryotic gene regulation is post-transcriptional in nature.  
Post-transcriptional regulation encompasses RNA processing, localization, 
translation and decay, as well as RNA stability throughout. These interconnected 
mechanisms provide complementary quality-control layers that collectively define 
the fate of every transcript (Moore 2005). Adding to the complexity, RNAs do not 
dwell alone in the cell, as they are ever accompanied by trans-acting factors, 
namely RBPs and non-coding RNAs, such as miRs, that bind cis-elements usually 
present in the 3´UTR (Kuersten and Goodwin 2003; Huntzinger and Izaurralde 2011). 
These are capable of adjusting the amount of gene product more rapidly, precisely 
and with a tactical reversibility option that transcriptional regulation alone cannot 
offer. It is this unique escort, their relative positions, and interactions that create a 
highly dynamic web of messenger ribonucleoprotein (mRNP) complexes, ruling RNA 
life. Indeed, Eukaryotic mRNPs have been functionally considered “post-
transcriptional operons” that markedly expand the regulatory elasticity of our 
surprisingly small genomes (Keene and Tenenbaum 2002; Keene 2007). Evidence in 
favour of this enticing RNA operon model on a genome-wide scale is mounting, as 
studies show that discrete subsets of mRNAs with shared sequence elements and 
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encoding proteins with common functions and locations are coordinately regulated 
by specific mRNPs (Gerber et al. 2004; Hogan et al. 2008).  
RNA processing starts in the nucleus, where precursor mRNAs acquire a 7-
methylguanosine cap structure at the 5' terminus (Lewis and Izaurralde 1997), a 
specialized poly(A) tail at the 3` end (Mangus et al. 2003), and introns are removed 
by splicing (Matlin et al. 2005). A major remodelling in mRNP composition occurs as 
mature mRNAs pass through the nuclear-pore complex (Köhler and Hurt 2007), with 
some factors remaining stably associated, whereas others are dynamically replaced 
by cytoplasmic counterparts. Upon export, several mRNAs are integrated in the 
translationally active pool, a process that remodels the protein coat and assembles 
polysomes. The canonical mechanism of translation is intricate and involves three 
coordinated events: initiation, elongation and termination (Jackson et al. 2010). On 
the other hand, some mRNAs are programmed for delayed translation, which allows 
transcripts to be transported to a specific subcellular localization or even stored until 
developmental or environmental cues call for their protein synthesis. These mRNAs 
are packaged into cytoplasmic mRNP granules that lack a limiting membrane and 
are visible under light microscopy, called processing bodies (P bodies) and stress 
granules (Anderson and Kedersha 2006).  
 
 
1.3.2  RNA-binding proteins and their biological functions 
An extensive computational analysis established that RBPs comprise 8 to 15% of 
the protein coding repertoire in eukaryotic genomes, highlighting both their ancient 
origin and the importance of RNA regulation in cell function (Anantharaman et al. 
2002). One possible explanation is that as highly specific processes to fine-tune gene 
expression evolved, a concomitant expansion of the number of RBPs needed has 
occurred. For example, at least 74% of human genes express multiple isoforms by 
using different exonic combinations through alternative splicing (Johnson et al. 2003). 
Its emergence during evolution drove the need for a corresponding increase in the 
number of RBPs, and it is also, in itself, a mechanism by which cells can expand their 
RBP repertoire.  
A subset of these proteins recognizes common features to almost every 
message, such as the 5`cap or the 3`poly (A) tail. However, the majority have a 
requirement for a primary sequence or type of secondary structure in which the 
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former is embedded, that are present in some mRNAs but not others. Their specificity 
is mediated by unique structural arrangements of individual RNA-binding domains 
whose properties are further moderated by auxiliary domains. This property, coined 
as “cooperative modularity”, accommodates different functionalities and allows for 
enormous combinatorial potential, further increasing affinity towards RNA (Lunde et 
al. 2007). To date, more than 40 different binding domains have been proposed, 
being the most frequent the RNA recognition motif. Other common classes include 
the K-homology (KH) domain, zinc-fingers of the CCCH and CCHC type, and the 
double-stranded RNA-binding domain.  
RBPs capacity to virtually regulate every aspect of RNA biogenesis and function 
is remarkable. In fact, they play pivotal roles during embryonic development 
(Kuersten and Goodwin 2003), and in a breath of several homeostatic processes 
such as synaptic plasticity (Luo et al. 2010), immune responses (Anderson 2008), 
epithelial cell proliferation (Yang et al. 2011), differentiation (Yang et al. 2010) and 
polarity (Nagaoka et al. 2012). With increasing knowledge on their importance, the 
more apparent it becomes that tampering with RBPs expression or function underlies 
the onset of several pathological conditions, including cancer (Lukong et al. 2008). 
Members of the signal transduction and activation of RNA (STAR) family of RBPs play 
vital roles in cell proliferation and differentiation. SAM68, for instance, is 
overexpressed in breast (Lukong et al. 2005) and prostate cancer cells (Busà et al. 
2007). On the contrary, Quaking (QKI) seems to function as a tumour suppressor in 
CRCs (Yang et al. 2010) and glioblastomas (Chen et al. 2012). 
 
 
 
 
 
   
Members of an evolutionarily-conserved family of RBPs, the MEX-3 family, are 
emerging as important post-transcriptional regulators of several cellular processes in 
diverse physiological settings. Their functions and underlying molecular mechanisms, 
particularly well-known for the ancestral mex-3 in the model organism 
Caenorhabditis elegans, are now described.  
 
1.4  THE MEX-3 FAMILY OF RNA-BINDING PROTEINS 
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1.4.1  Caenorhabditis elegans MEX-3 
In the worm embryo, normal development requires precise spatial and 
temporal expression patterns of maternal mRNAs, such as the anteriorly localized 
membrane receptor glp-1 and the posteriorly localized transcription factor pal-1, the 
Drosophila notch and cad orthologues, respectively (Evans and Hunter 2005). The 
correct distribution of these messages that act to direct lineage-specific 
commitment patterns from individual blastomeres, is determined by partitioning-
defective (par) genes, which are required to establish polarity and whose disruption 
cause the earliest and most extensive embryonic abnormalities (Kemphues et al. 
1988; Goldstein and Macara 2007). Molecular evidence places C. elegans MEX-3 
amid both classes, an intermediate regulator of cell fate determinants under par-
dependent control, thus acting as a critical component in the link between cell 
polarity and asymmetric gene expression (Huang et al. 2002).  
mex-3 gene encodes a protein with two seventy-amino acid regions that are 
40% identical to each other. The repeated sequences correspond to putative RNA-
binding motifs, initially identified in the pre-mRNA-binding heterogeneous nuclear 
ribonucleoprotein (hnRNP) K  and named KH domains (Siomi et al. 1993). MEX-3 
interacts with a minimal MEX-3 recognition element (MRE), defined as the 
degenerate consensus sequence (A/G/U)(G/U)AGN(0-8)U(U/A/C)UA (Pagano et al. 
2009). Mutations disrupting the mex-3 locus are fully penetrant, recessive, strict 
maternal-effect and embryonically lethal, resulting in embryos that abnormally 
generate body-wall muscle from the anterior blastomere (AB), hence the name mex 
for “muscle excess” (Draper et al. 1996). This homeotic transformation is due, in part, 
to the function MEX-3 exerts over the transcription factor pal-1, the orthologue of 
CDX genes in mammals, and the somatic determinant of posterior identity (Hunter 
and Kenyon 1996). mex-3 mRNA and protein accumulate cytoplasmically and are 
unevenly distributed in early embryos (Draper et al. 1996). After fertilization and 
between the two and four-cell stage, MEX-3 is preferentially localized to the AB 
lineage, disappearing afterwards in a pattern similar to that described for other 
maternal mRNAs (Seydoux and Fire 1994). On the other hand, while pal-1 mRNA is 
present throughout the early embryo, PAL-1 protein is asymmetrically localized and 
only detected from the four-cell stage onwards in descendants of the posterior (P1) 
blastomere lineage, thus correlating with low MEX-3 levels (Figure 3A). In 
accordance, PAL-1 is ectopically expressed in all cells of mex-3 mutant embryos and 
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MEX-3 has been shown to repress translation of a lacZ RNA reporter construct 
containing the pal-1 3`UTR in anterior blastomeres (Hunter and Kenyon 1996). 
Therefore, MEX-3 plays a crucial role as a translational repressor of pal-1, specifying 
proper blastomere identity during early embryogenesis. 
Post-transcriptional regulation of maternal RNAs is also a primary mechanism to 
control gene expression in C. elegans germline, and MEX-3 contributes to the 
maintenance of germ cell totipotency in the adult worm (Ciosk et al. 2006). The 
hermaphrodite germline is a highly dynamic organ presenting a stereotypical 
organization of gametes commitment: the most distal end of the gonad is a 
proliferative compartment containing mitotic cells that progressively enter meiosis in 
a central syncytial region. Spontaneous germ cell death by apoptosis or 
differentiation into sperm cells (late L4 larval stage) and oocytes (adulthood) occurs 
in the proximal gonad. Switches between these different stages involve spatially non-
overlapping translational regulation of target mRNAs by the RBPs defective in 
germline development (GLD-1) and MEX-3 (Lee and Schedl 2001; Mootz et al. 
2004) (Figure 3B). In maturing oocytes, MEX-3 also mediates pal-1 inhibition; 
combined with GLD-1 action, this ensures that embryos do not inherit maternal PAL-1 
protein and develop properly (Draper et al. 1996; Mootz et al. 2004). In accordance, 
double mutant strains for mex-3 and gld-1 develop a germline tumour containing 
numerous cells of muscular, neuronal and intestinal nature, reminiscent of human 
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teratomas (Ciosk et al. 2006). This germ cell transdifferentiation seems to be the end 
result of an abnormal expression of somatic determinants such as PAL-1.  
 
 
1.4.2  The mammalian MEX3 proteins 
C. elegans mex-3 was identified and characterized in humans as a family of 
four homologous genes called MEX3A to MEX3D (Buchet-Poyau et al. 2007). These 
are located at chromosomic positions 1q22, 15q25.2, 18q21.2 and 19p13.3, 
respectively, and are composed of two exons and one intron. The closely related 
encoded proteins contain two tandemly repeated KH domains that putatively 
provide RNA-binding properties. Additionally, they possess a carboxy-terminal really 
interesting new gene (RING) finger module, not present in the nematode MEX-3 and 
believed to mediate protein-protein interactions. Four mouse orthologues were also 
identified displaying strong similarity at the amino acid level to their human 
counterparts. For these characteristics they are also known as RING finger and KH 
domain-containing (RKHD) proteins.  
Expression analysis of the MEX3 transcripts in different human tissues showed 
that MEX3D is ubiquitous, while the others have a varied expression pattern, with the 
highest level found in fetal brain and testis (Buchet-Poyau et al. 2007). 
Overexpression experiments demonstrated that MEX3 are phosphoproteins that 
shuttle between the nucleus and the cytoplasm by the CRM1-dependent export 
pathway and via an N-terminally located export signal. Confocal microscopy 
analysis revealed co-localization of MEX3A and MEX3B with DCP1A and AGO family 
members, being the latter catalytic components of the RNA-induced silencing 
complex (RISC), the key effector of miR and RNA interference (RNAi) pathways. This 
association was restricted to P bodies, which are known sites of mRNA turnover 
(Eulalio et al. 2007). These results together with the ability of MEX3 proteins to interact 
in vitro with poly(A) ribonucleotide homopolymers and certain cellular mRNAs, 
indicate that MEX3 proteins constitute novel human RBPs potentially involved in post-
transcriptional regulatory networks (Donnini et al. 2004; Buchet-Poyau et al. 2007; 
Courchet et al. 2008). Nevertheless, the specific biological role of each member was 
basically unknown during the course of this work, and only recently started to be 
explored in more detail.  
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The homeobox transcription factor CDX2 is determinant for proper embryonic 
development, as well as for endodermal induction and adult maintenance of the 
intestinal epithelium. Besides this homeostatic function, in vitro experiments, animal 
models and human lesions show that de novo expression of CDX2 is associated with 
ectopic foci of intestinal differentiation, which in turn conveys an increased risk of 
cancer development. A paradigmatic example of this link is provided by gastric IM, 
a lesion that encompasses a tissue adaptive response to H. pylori infection and 
subsequent chronic inflammatory reaction. The role of bacterial eradication as a 
common preventive strategy against gastric cancer development remains 
debatable and largely dependent on the extent of preneoplastic changes at the 
time of treatment, given the apparent stability of the CDX2-dependent IM 
phenotype. Moreover, the nature of CDX2 involvement in the establishment and/or 
progression of CRC is far from being consensual. Early data suggested that loss of 
CDX2 was a common event; however, ensuing studies have shown that its expression 
is retained and in some cases even increased. Therefore, defining a thorough 
portrayal of the CDX2 regulatory network stands out as a leading investigation 
priority, not only to advance its specific contribution to these carcinogenic 
processes, but most importantly to apply the acquired knowledge in the design of 
alternative and perhaps more target-oriented therapeutic strategies. 
The present work, framed within the abovementioned conceptions, intends to 
uncover new molecular mechanisms of CDX2 regulation focusing on the role of yet 
poorly-described microenvironmental influences as a research guiding line. In this 
regard, the following specific objectives are proposed: 
 
1. Evaluate if methylation at the promoter level is a mechanism involved in the 
regulation of CDX2 gene expression 
DNA methylation is an epigenetic mechanism of transcriptional regulation and 
a direct measure of the environmental effect over the genome, with an involvement 
in cancer attributed to the inappropriate silencing of tumour suppressor genes 
(hypermethylation), or loss of oncogene repression (hypomethylation).  
Previous studies reported that the methylation status of CDX2 might have a 
relevant regulatory role in different contexts. But they present discrepancies, both 
concerning the region of query and the methods employed to analyse it. The lack of 
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a comprehensive analysis led us to evaluate if methylation at the promoter level 
could be a mechanism involved in the regulation of CDX2 expression, and the 
obtained results are presented in Chapter 2. We hypothesized that in intestine, where 
CDX2 is expressed, the gene would be unmethylated, while in the normal gastric 
mucosa, where CDX2 is not detected, the gene would be methylated. The process 
of H. pylori infection and accompanying inflammatory response would in some way 
be responsible for promoter demethylation, constituting the triggering event leading 
to the development of IM. The alteration in CDX2 methylation profile along the 
gastric carcinogenic process would constitute a proof of concept, undoubtedly 
establishing the relevance of this mechanism and contributing to settle a contentious 
question in the field.   
 
2. Assess the role of cell-matrix interactions in the regulation of CDX2 
expression 
For many years now, traditional methods of cell culture have produced 
important conceptual advances in cancer research. Nevertheless, cells grown on 
flat substrates can differ considerably in their morphology, differentiation, cell-cell 
and cell-matrix interactions from those growing in more physiological conditions. At 
the other end of the spectrum we have whole-animal models, which frequently 
corroborate the importance of particular processes. But these are complex, 
expensive and not easily manipulated. By mimicking features of the in vivo 
microenvironment and taking advantage of the same tools used to study cells in 
standard culture, 3D cell/tissue models have been bridging the gap between both, 
providing unique perspectives on the behaviour of stem cells, epithelial tissues and 
tumours.  
Earlier publications described the role of epithelial-mesenchymal interactions as 
determinant for the expression of CDX2, not only for proper spatio-temporal 
induction of intestinal differentiation, but also in modulating its levels during 
carcinogenesis. However, the direct molecular mediators responsible for this 
adaptable response remained for the most part elusive. In Chapter 3, we present 
results regarding the establishment of in vitro 3D cell culture models comprising 
gastric cancer cell lines and an extracellular matrix. We hypothesized that this 
approach, exploratory in nature, would allow pinpointing regulatory factors and 
signalling pathways involved in the control of CDX2 expression.    
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3. Determine if the RNA-binding protein MEX3A retains a repressive function 
over CDX2 
Post-transcriptional mechanisms are now considered at least as equally 
important as transcriptional ones for the life of the cell, adding further complexity 
to gene regulatory networks. The modulation of the cell culture microenvironment 
achieved in the previous chapter, fused with high-throughput genome-wide 
screening, led to the identification of a target putatively involved in CDX2 regulation, 
called mex-3 homologue A (MEX3A).  
In C. elegans, MEX-3 plays a crucial role as a translational repressor of pal-1, the 
CDX orthologue, specifying blastomere identity during embryogenesis. Although the 
mammalian MEX3 family members had been shown to interact in vitro with RNAs, 
their biological role was essentially unknown. We hypothesized that the RNA-binding 
protein MEX3A could have an evolutionarily conserved role in inhibiting CDX2 
expression, this case in the GI context. In Chapter 3, we challenge this idea by 
performing diverse cell-based assays together with expression studies in murine 
intestine, with the objective of unravelling mechanistic and functional aspects 
behind such regulation. In Chapter 4, we highlight recent scientific advancements 
on the function of the mammalian MEX3 proteins, comparing common aspects of 
biological relevance, discussing their putative importance in development and 
disease, and also raising future points of interest in this research area.  
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CDX2 promoter methylation is not associated with mRNA expression 
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Dear Sir, 
Yuasa et al.1 published that specific lifestyle factors, 
described to be potentially preventive of gastric cancer on epi- 
demiological basis, may directly influence the carcinogenic 
process by affecting demethylation or maintenance of unme- 
thylated status of selected genes. Specifically, it was shown 
that CDX2 was methylated in 23.6% of primary gastric carci- 
nomas, whereas no methylation was seen in adjacent noncan- 
cerous gastric tissue of some of the cancer patients studied. 
They also demonstrated a significant inverse association 
between intake of green tea (more than 7 cups/day) and the 
methylation status of CDX2 in gastric cancer patients. How- 
ever, in the same article, the authors did not show that the 
methylation status was correlated with CDX2 expression. In 
our study, we investigated if methylation of the CDX2 pro- 
moter could be a mechanism involved in the regulation of 
CDX2 expression in gastric carcinomas using gastric carci- 
noma cell lines as models and also in intestinal metaplasia 
(IM) of the stomach. CDX2 is a transcription factor that plays 
a major role in intestinal differentiation both in the intestine 
and in aberrant locations, such as in IM of the stomach.2,3 We 
show that there is no association between CDX2 promoter 
methylation and CDX2 expression, suggesting that methyla- 
tion does not constitute a primary mechanism regulating 
CDX2 expression both in gastric carcinoma cell lines and in 
gastric preneoplastic lesions. Thus, our findings do not support 
the conclusions taken by Yuasa et al.1 
We used the bioinformatic tool CpGPlot to search for poten- 
tial CpG islands in the proximal region of the CDX2 promoter 
and identified two regions that fulfil the criteria (Fig. 1a). Then 
we studied the basal CDX2 mRNA expression and the methyl- 
ation status of the CDX2 promoter in a panel of four human 
gastric carcinoma cell lines (AGS, GP202, IPA220 and 
MKN45). CDX2 mRNA expression analysis in the gastric car- 
cinoma cell lines showed that AGS and IPA220 strongly 
express CDX2, while GP202 and MKN45 present equally low 
levels of CDX2 expression (Fig. 1b). The methylation of the 
CDX2 promoter in these cell lines was determined using the 
bisulfite-genome sequencing method (Fig. 1c). CpG island 1 
was methylated in all cell lines, whereas CpG island 2 was 
methylated in GP202 and AGS cell lines and unmethylated in 
IPA220 and MKN45 cell lines. These results did not correlate 
with CDX2 mRNA expression. To further confirm if methyla- 
tion could be in any way involved in CDX2 regulation, we 
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treated these cell lines with the demethylating agent 5-aza-2’- 
deoxycytidine (Fig. 1d). Once more, the results obtained sug- 
gest that methylation is not directly regulating CDX2 expres- 
sion since cell lines with similar basal methylation status, AGS 
and GP202, react differently to the treatment with a demethy- 
lating agent. Although there is an increase of expression in 
GP202 after treatment, CDX2 remains unchanged in AGS. 
Strikingly, MKN45 which shows unmethylated CDX2 pro- 
moter also reacts to the treatment with an increased expres- 
sion. 
Furthermore, we examined CDX2 expression and the meth- 
ylation status of 42 CpG sites, contained in CpG island 2 of the 
CDX2 promoter, in two specimens of normal gastric mucosa, 
adjacent IM foci and in two normal colonic mucosa samples. 
As expected no CDX2 expression was observed in normal gas- 
tric mucosa in contrast to IM and colonic tissue (data not 
shown). The methylation pattern was inconsistent and no cor- 
relation was found with CDX2 expression in all samples (Fig. 
2). 
In summary, and although previous studies show that meth- 
ylation might be involved in CDX2 regulation,4–7 our in vitro 
and in vivo results demonstrate that the pattern of methylation 
at the CDX2 promoter is random and unrelated with its expres- 
sion. The increase in CDX2 expression observed in some of 
the cell lines studied is more likely due to the effect of the 
demethylating agent over epigenetically modified regulators, 
such as silenced transcription factors or modified histones,8 
and not directly over CDX2. 
Yours sincerely, 
Bruno PEREIRA, Carla OLIVEIRA, Leonor DAVID, Raquel 
ALMEIDA* 
 
Acknowledgements 
 
The authors thank Paula Silva for excellent technical sup- 
port in tissue microdissection. 
 
 
 
 
 
 
Fundação para a Cieˆncia e Tecnologia, Programa Operacional Cieˆncia, 
Tecnologia e Inovação do Quadro Comunitário de Apoio III (Project 
PTDC/SAU-OBD/64490/2006), European Funding FEDER. 
*Correspondence to: Institute of Molecular Pathology and Imm- 
unology of the University of Porto (IPATIMUP), Rua Dr. Roberto Frias 
S/N 4200-465 Porto, Portugal. Fax: +35-122-5570799. 
E-mail: ralmeida@ipatimup.pt 
Received 17 March 2009; Accepted after revision 21 April 2009 
DOI 10.1002/ijc.24544 
Published online 27 April 2009 in Wiley InterScience (www.interscience. 
wiley.com). 
 37  
CHAPTER 2.  CDX2 PROMOTER METHYLATION 
 
 
 
 
 
 
  
1740 PEREIRA ET AL. 
 
 
 
 
 
 
 
 
   FIGURE 1 – Methylation status of CDX2 in a panel of human gastric cancer cell lines and functional relation with CDX2 mRNA expression. 
(a) Schematic representation of the 5`proximal flanking region of CDX2 gene. Thin vertical lines mark the location of CpG dinucleotides. A 
box indicates the first exon, including non-coding (white) and coding (black) sequences. Two putative CpG islands were identified with the 
online bioinformatic tool CpGPlot (www.ebi.ac.uk/tools/emboss/cpgplot), one in the promoter region (–1603bp to –1197bp) and another in the 
first exon, including the coding region (–22bp to +660bp). Arrow-heads indicate the position of bisulfite specific primers. (b) RT-PCR analysis 
of CDX2 mRNA expression in gastric cancer cell lines. GAPDH mRNA expression was used as an internal loading control and NTC indicates 
no template control. (c) Methylation profile of CDX2 in gastric cancer cell lines obtained by direct sequencing of bisulfite-treated genomic 
DNA. M, methylated; U, unmethylated. (d) Real-time PCR for CDX2 expression in human gastric cancer cell lines after treatment with the 
demethylating agent 5-aza-2`-deoxycytidine (5azaDc, Sigma) during different time-points. Each experiment was carried out in triplicate at least 
twice; the results are expressed as mean ± SD of biological replicas. The values obtained with vehicle-treated cells were referred to as 1. CDX2 
mRNA levels were normalized with the corresponding 18S rRNA levels. 
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FIGURE 2 – Bisulfite DNA sequencing of the first and second fragments of CDX2 CpG island 2 in two specimens of the gastric mucosa and ad- 
jacent IM foci (S1 and S2) and in two specimens of normal colonic mucosa (S3 and S4). Only clearly identifiable normal gastric glands and 
metaplastic glands were selected using a PALM Microbeam Microscope (Zeiss). With this methodology we were able to minimize stromal cell 
contamination in our tissue samples. PCR amplicons from the tissues were cloned into pCR4-TOPO vector using the TOPO TA Cloning kit 
(Invitrogen), and at least five individual clones from each sample were sequenced using the ABI Prism BigDye Terminator v3.1 Cycle Sequenc- 
ing kit (Applied Biosystems) with a reverse M13 primer. Each horizontal row of circles represents analysis in a single clone of bisulfite-treated 
DNA of the 42 CpG sites contained in the mentioned region. Solid and open circles represent methylated and unmethylated CpG sites, respec- 
tively. 
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ABSTRACT 
 
The homeobox transcription factor CDX2 plays a 
crucial role in intestinal cell fate specification, both 
during normal development and in tumorigenic 
processes involving intestinal reprogramming. The 
CDX2 regulatory network is intricate, but it has not 
yet been fully uncovered. Through genome-wide 
screening of a 3D culture system, the RNA-binding 
protein MEX3A was identified as putatively involved 
in CDX2 regulation; therefore, its biological rele- 
vance was addressed by setting up cell-based 
assays together with expression studies in murine 
intestine. We demonstrate here that MEX3A has a 
repressive function by controlling CDX2 levels in 
gastric and colorectal cellular models. This is 
dependent on the interaction with a specific 
binding determinant present in CDX2 mRNA 
3`untranslated region. We have further determined 
that MEX3A impairs intestinal differentiation and 
cellular polarization, affects cell cycle progression 
and promotes increased expression of intestinal 
stem cell markers, namely LGR5, BMI1 and MSI1. 
Finally, we show that MEX3A is expressed in 
mouse intestine,  supporting  an  in vivo context for 
interaction with CDX2 and modulation of stem cell 
properties. Therefore, we describe a novel CDX2 
post-transcriptional regulatory mechanism,  
through the RNA-binding protein MEX3A, with a 
major impact in intestinal differentiation, polarity 
and stemness, likely contributing to intestinal 
homeostasis and carcinogenesis. 
 
 
INTRODUCTION 
The homeodomain transcription factor CDX2 is a critical 
determinant of intestinal homeostasis, both during devel- 
opment and throughout adult life. CDX2 is involved in       
the antero-posterior patterning of the mammalian embryo  
and is the key molecular mediator of intestinal differenti- 
ation (1–4). Furthermore, multiple evidences substantiate 
CDX2 crucial role in carcinogenesis of the digestive tract.    
It was shown to inhibit cell growth and migration in vitro    
as well as dissemination of colon tumour cells in vivo (5). 
CDX2 heterogeneous loss has also been observed in colo- 
rectal carcinomas (CRCs), particularly in invasive cells        
at the tumour edge (6). Moreover, CDX2 reduction    
increases the progression of chemically induced CRCs      
(7). Conversely, under certain pathological conditions,  
CDX2 becomes abnormally expressed in other organs of    
the digestive tract besides intestine, namely the esophagus
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(8) and stomach (9,10), driving a precancerous lesion   
known as intestinal metaplasia, a process conﬁrmed in 
transgenic mouse models (11,12). 
Owing to the essential function in intestinal    
development, differentiation and carcinogenesis, CDX2    
regulation has been extensively studied. We have previously 
identiﬁed different mechanisms involved in the tran- 
scriptional regulation of this gene such as the Bone 
morphogenetic protein (BMP) pathway (13), SOX2 (14)   
and a CDX2 autoregulatory loop (15).  Several transcription 
factors including HNF4a, GATA6, TCF4 and                       
β-catenin were shown to interact with Cdx2 promoter 
fragments (16). However, mutations at the CDX2 locus      
are a rare event in CRC (17), and its expression does          
not depend on methylation of the proximal promoter        
(18). On the other hand, CDX2 protein phosphorylation     
has also been shown to modify its activity in intestinal      
cells (19,20). These and other studies support the notion    
that CDX2 regulation is intricate and strictly controlled. 
During the past two decades, post-transcriptional regu- 
lation emerged as a fundamental mechanism guiding gene 
expression in higher eukaryotic cells, being at the core of 
normal cellular processes but also cancer initiation and 
development. It is now increasingly clear that RNA matur- 
ation, localization, translation and stability provide     
multiple layers of spatio-temporal control determining a 
transcript’s fate (21,22). These coupled events are generally 
dependent on the cooperation between cis-regulatory 
elements and trans-acting factors, such as non-coding     
RNAs and RNA-binding proteins (RBPs). RBPs have      
been implicated in virtually every aspect of RNA metabol-   
ism (22,23), particularly, their repressive role is critical to 
establish precise translational patterns that deﬁne develop-
mental and differentiation switches in many organisms. 
In Caenorhabditis elegans, MEX-3 is a translational  
repressor that regulates blastomere identity during early 
embryogenesis (24) and germline totipotency in the adult 
worm (25). MEX-3 has two K homology domains, which 
are conserved single-stranded RNA-binding motifs (26). 
Mutations disrupting mex-3 locus are lethal, resulting in 
embryos that inappropriately generate body-wall muscle 
from the anterior blastomere; hence, the name mex for 
‘muscle excess’. This is speciﬁed, in part, by the repressive 
function that MEX-3 exerts over the transcription factor   
pal-1, the C. elegans orthologue of caudal in Drosophila   
and CDX in mammals (24,27). In humans, mex-3 was 
identiﬁed and characterized as four homologous genes, 
MEX3A–D (28,29), whose biological relevance is starting    
to be explored. Recently, the functional role of MEX3C       
as a RNA-binding ubiquitin E3 ligase was established, 
mediating the post-transcriptional decay of HLA-A    
allotypes (30). It was also shown to be necessary for    
normal postnatal growth in mutant mice by enhancing        
the local expression of insulin-like growth factor 1 in       
bone  (31)  and  appears  to  be  involved  in  metabolic  
regulation of energy balance (32), through yet unknown  
effectors. A variant form of MEX3D called TINO was  
shown to negatively regulate the antiapoptotic protein    
BCL-2 in HeLa cells (33). Finally, knockdown of      
MEX3A by siRNAs was shown to suppress cell prolifer- 
ation and migration in human gastric cancer cells, but the   
molecular mechanisms behind these ﬁndings were not ad- 
dressed (34). Pursuing the aim of uncovering new CDX2 
regulatory  mechanisms,  we  explored  a  putative  transla- 
tional repression by MEX3A, which was inversely       
correlated with CDX2 in a 3D experimental model. By  
studying MEX3A expression in vivo and using a cell                          
line-based approach to modulate its levels in vitro, our        
study describes a novel post-transcriptional process by       
which CDX2 expression is impaired in the gastrointestinal 
setting and intestinal-like homeostasis compromised,      
through alterations in differentiation, polarity and          
stemness features. Another layer of control is thus added          
to the complex CDX2 regulatory network, involving      
MEX3A as a key regulator of intestinal homeostasis,                      
which  might  have  signiﬁcant  implications  to  gastrointes-   
tinal carcinogenesis. 
 
 
MATERIALS AND METHODS 
Cell culture and treatments 
 
Human gastric carcinoma cell line AGS (ATCC,         
American Type Culture Collection) and CRC cell line                  
Caco-2 (ATCC) were cultured under standard conditions         
in RPMI-1640 medium and Dulbecco’s modiﬁed Eagle’s       
medium, respectively, containing 10% fetal bovine serum,    
100 U/ml of penicillin and 100 µg/ml of streptomycin (Life 
Technologies). For the AGS 3D culture, ﬂasks were         
coated with 50 µl/cm2 of matrigel basement membrane         
(BD Biosciences) at a 1.5:1 proportion to serum-free  
medium. A 2 x 104 cells/cm2 suspension was seeded on                         
top and maintained for 14 days with medium change          
every 2 days. For the Caco-2 3D culture, coverslips were 
coated with 60 µl/cm2 of matrigel.  A 6 x 103 cells/cm2 
suspension plus 2% matrigel was seeded on top and main- 
tained for 8 days with medium change every 2 days.               
To quantify lumen formation, >100 cysts were microscop- 
ically examined. For proteasome inhibition, cells were     
treated with 25 µM MG132 (Calbiochem) or vehicle                    
treated with DMSO. To inhibit transcription, cells were 
exposed to 10 µg/ml of Actinomycin D (Sigma). 
 
Constructs and site-directed mutagenesis 
 
The previously published pCMV-MEX3A expression       
vector (28) was used together with a pCMV-Tag3B           
empty vector (Agilent Technologies) in transfections.              
A pRLControl construct containing a humanized Renilla 
luciferase (Rluc) coding sequence (35) was used as a    
backbone to create the pRLCDX2 vector, encoding  a  
luciferase fusion transcript to the parental CDX2    
3`untranslated region (UTR). The QuickChange site-     
directed mutagenesis kit (Stratagene) was then used to 
introduce speciﬁc mutations in the previous plasmid, to 
generate the pRL∆CDX2 construct, with a mutated           
MEX-3 recognition element (MRE). Oligonucleotides 
containing the desired mutations were designed according       
to the manufacturer’s instructions (Supplementary Table   
S1). Taking into account the degenerate consensus               
sequence described for MEX-3 binding in C. elegans, a      
mutational background of Cytidine was used because pre- 
sumably this base is not tolerated in the MRE (36).
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Transfections, RNAi and luciferase assays 
 
Transient transfections were done using Lipofectamine    
2000 reagent according to the manufacturer’s guidelines 
(Life Technologies). A DNA (µg) to Lipofectamine 2000 
reagent (µl) ratio of 1:1.5 in OPTI-MEM medium was  
used for routine transfection experiments of expression 
vectors. For stable transfections, selection was initiated    
48h post-transfection in medium supplemented with            
0.6 mg/ml of G418 (Sigma). Neomycin-resistant positive 
clones obtained through limiting dilution were routinely 
maintained with 0.2 mg/ml of G418. A commercial set of 
three Stealth Select siRNA duplexes (HSS150674, 
HSS150675 and HSS150676) directed against human 
MEX3A (Life Technologies) and a custom set of three 
siRNA duplexes directed against CDX2 were used with 
scrambled controls. An siRNA duplexes (pmol) to 
Lipofectamine 2000 reagent (µl) ratio of 20:1 in OPTI- 
MEM medium was used for inhibition experiments. 
Luciferase reporter assays were performed with the Rluc 
Assay System (Promega), and β-galactosidase activity was 
used for normalization of experimental variations. 
 
RNA isolation and quantitative real-time PCR 
 
Total RNA was extracted using TRI Reagent (Sigma) and 
reverse transcribed using the Superscript II Reverse 
Transcriptase kit (Life Technologies). Analysis of BMI1, 
CDX2,  GAPDH,  LGR5,  MEX3A  and  Rluc  mRNA 
expression was performed in an ABI Prism 7500 system 
using SYBRgreen reagent (Life Technologies) and speciﬁc 
primer pairs (Supplementary Table S1). Each sample was 
ampliﬁed in triplicate and speciﬁcity conﬁrmed by dissoci- 
ation analysis. The 18S rRNA expression was measured for 
normalization of target gene abundance. 
 
Microarrays and data processing 
 
Experiments were performed at the National Facility for 
DNA Microarrays (Aveiro, Portugal). Three independent 
2D and 3D AGS cell cultures were selected for total RNA 
extraction using TRI Reagent. RNA quantity and quality 
were assessed using the Nanodrop ND-1000 (Thermo 
Scientiﬁc) and 2100 Bioanalyzer (Agilent Technologies) 
systems, and only samples with a RNA integrity number 
above nine were considered for further study. Preparation 
and labelling of the RNA was performed using the       
One-Color Microarray-Based Gene Expression Analysis 
Quick Amp Labelling kit (Agilent Technologies). Brieﬂy, 
600 ng of total RNA from 2D and 3D biological replicas 
was used as input together with spike-in controls to 
generate Cyanine 3-labelled cRNA. The ampliﬁed cRNA 
samples were puriﬁed with RNeasy Mini kit (Qiagen) and 
hybridized to Human Gene expression 4 x 44K v2 
Microarray slides (Agilent Technologies) at 65oC for       
17h. After washing procedures, images of the hybridiza- 
tions were acquired using a G2505B Microarray Scanner 
(Agilent Technologies). The Feature Extraction software 
was used for spot identiﬁcation, background subtraction 
and quantiﬁcation of the ﬂuorescent signal. Raw expres- 
sion data were processed using BRB-ArrayTools v3.8.1 
software  (37).  After  base  2  log  transformation  and
average of probe replicates, normalization was applied    
using the median intensity over the entire array to   
minimize systematic variance. Differentially expressed 
transcripts between the two culture conditions were    
ﬁltered using the Class Comparison tool, performing an 
unpaired sample t-test with a P < 0.01 and considering a 
minimal 1.5-fold change. Hierarchical clustering analysis   
of signiﬁcantly altered genes was conducted in TIGR 
MultiExperiment Viewer v4.8.1 software (38) using 
Euclidean correlation and average linkage clustering, and 
expression values indicated colorimetrically. Functional 
annotation of differentially expressed genes, identiﬁed by 
extending the unpaired t-test parameter to P < 0.05 and 
maintaining the minimal fold change was performed      
with DAVID program (39). Microarray data have been 
submitted to the ArrayExpress database (http://www.ebi. 
ac.uk/arrayexpress/) and assigned the identiﬁer E-MTAB- 
1234. The complete list of differentially expressed genes is 
detailed in Supplementary Table S2. 
 
Protein extraction and western blot analysis 
 
Cells were lysed for 30 min on ice in a lysis buffer 
containing 20 mM  Tris–HCl  (pH  7.5),  150 mM  NaCl,    
2 mM ethylenediaminetetraacetic acid and 1% IGEPAL 
(Sigma), supplemented with Complete protease inhibitor 
cocktail (Roche Applied Science), 1 mM PMSF and 1 mM 
Na3VO4. Lysates were centrifuged at 12 000 rpm for 20  
min at 4oC and the supernatant recovered. Protein con-
centration was determined using the BCA Protein Assay 
Reagent (Thermo Scientiﬁc). Protein extracts (30–50 µg) 
were run on 10% sodium dodecyl sulphate–polyacryl- 
amide gel electrophoresis, transferred to a nitrocellulose 
membrane, blotted overnight with appropriate antibodies 
(Supplementary Table S1), and signals revealed with     
ECL detection kit (GE Healthcare Life Sciences). Actin 
levels were used to normalize protein expression, and 
quantiﬁcation of western blots was performed using Fiji 
software (40). 
 
Flow cytometry 
 
Caco-2 cells were harvested 48 h after transfection at con- 
ﬂuence and ﬁxed with 1% paraformaldehyde for 20 min     
at room temperature followed by permeabilization with 
0.1% Triton X-100 (Sigma) for 5 min on ice. Staining     
was performed with anti-MEX3A antibody and visualized   
with goat anti-rabbit FITC-conjugated secondary    
antibody. For DNA content assessment, cells were 
incubated with a propidium iodide (50 µg/ml) and       
RNAse A (200 µg/ml) solution (Sigma) for 30 min at room 
temperature. Samples were read in a FACSCanto                
II (BD Biosciences) ﬂow cytometer, and analysis was 
performed using the FlowJo software. 
 
RNA-immunoprecipitation assay 
 
Cells were lysed 48 h after transfection as indicated for 
protein extraction but with the addition of 20 U/ml of 
RNAseOUT Ribonuclease inhibitor (Life Technologies). 
Before the lysis procedure, cells were washed with phos- 
phate buffered saline (PBS) and subjected to ultraviolet 
crosslink   (254-nm   wavelength)   at   an   energy   level
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  of 1.8 J/cm
2 on ice for 20 min.  Immunoprecipitation       
from protein extracts (750 µg) was performed overnight   
with anti-myc antibody (Clontech) or normal mouse 
immunoglobulin G (IgG) (Millipore) and RNA- 
immunocomplexes recovered by incubation with protein     
G-sepharose bead slurry (Sigma) for 2 h in the following  
day. After ﬁve washes in lysis buffer containing 
RNAseOUT, RNA was extracted from the bead slurry         
as indicated before and resuspended in 10 ml of dH2O.     
RT-quantitative real-time PCR (qPCR) analysis was   
directly performed on the RNA as described. Target     
mRNA levels immunoprecipitated in the MEX3A trans- 
fected cells were normalized to the levels recovered in the 
empty vector transfected cells. 
 
Immunoﬂuorescence and microscopy 
 
Cells grown on coverslips were ﬁxed using ice-cold 
methanol for 10 min. For Caco-2 3D assay, cysts were    
ﬁxed with a 2% paraformaldehyde and 0.05% glutar- 
aldehyde solution at room temperature for 20 min,    
followed by quenching with 0.1% NaBH4 and permeabil- 
ization with 0.5% Triton X-100. Parafﬁn-embedded        
wild-type murine tissue sections (4 mm) were deparafﬁnized 
with clear-rite (Thermo Scientiﬁc) and rehydrated. All 
samples were blocked with non-immune serum diluted in 
10%   BSA–PBS,  followed  by  incubation  with  appropriate 
 
antibodies (Supplementary Table S1) diluted in 5% BSA– 
PBS. Nuclei were counterstained with 4`,6-diamidino-         
2-phenylindole (DAPI, Sigma), and coverslips mounted on 
microscope slides with Vectashield (Vector). Imaging 
acquisition was based on optical sectioning and adjusted    
for brightness and contrast with Fiji software (40). Imaging 
was performed on an Axio Imager Z1 (Zeiss) Fluorescence 
microscope with an ApoTome attachment (Figures 3, 7     
and 8 and Supplementary Figure S4), and on a TCS          
SP5 II (Leica) Laser Scanning Confocal microscope 
(Supplementary Figure S1). The middle focal plane of         
Z-stack images with similar total number of planes were   
used for representation of cysts polarity. 
 
Statistics 
 
Each experiment was carried out in triplicates at least      
three times, and data were expressed as means ± SD. 
Statistical analysis was performed using Student’s t-test.      
A P < 0.05 was considered as signiﬁcantly different. 
 
 
RESULTS 
CDX2 expression is downregulated in AGS cells 
cultured in matrigel 
 
In an effort to study CDX2 regulation in a physiologically 
relevant      microenvironment,      we      compared      CDX2 
 
 
 
 
Figure 1. Establishment of AGS 3D cultures and characterization of CDX2 expression. (A) Schematic representation of the culture systems and               
cellular morphology at culture day 4 in bright ﬁeld microscopy (original magniﬁcation, x100). (B) Western blot and qPCR of CDX2 expression in                   
2D and 3D after 2 weeks culture. Cardinal numbers represent biological replicates. Values for CDX2 mRNA expression in 2D culture were referred                  
to as 1. (C) Western blot of CDX2 protein expression on treatment with MG132. (D) qPCR of CDX2 mRNA expression on  treatment with               
actinomycin D. Expression levels in the absence of treatment were set at 100%. Depicted half lives were calculated using exponential regression                   
(**P = 0.003). 
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expression in AGS cells cultured in a standard 2D condi-   
tion versus a 3D condition with matrigel. Cells depicted 
distinct growth patterns amongst both settings, forming a 
compact monolayer and conspicuous multicellular aggre- 
gates, respectively (Figure 1A). Although there was a 
dramatic decrease in CDX2 protein levels in the 3D    
culture, mRNA showed heterogeneous levels without cor- 
relation with protein (Figure 1B). Treating cells with the 
proteasome inhibitor MG132 indicated that CDX2 
downregulation was not related to an increase in  
proteasome-dependent degradation (Figure 1C). On the other 
hand, we found a signiﬁcant difference in CDX2          
mRNA stability after actinomycin D treatment to                       
inhibit transcription (Figure 1D). The CDX2 mRNA        
half-life    value    was    higher    for    the    2D    culture 
(166.9 ± 15.5 min) than for the 3D culture (62.9 ± 22.1   
min). These results suggest the existence of a post- 
transcriptional regulatory mechanism, probably acting       
over CDX2 mRNA. 
With  the  objective  of  pinpointing  the  mechanism 
underlying CDX2 downregulation, we performed a      
whole-genome expression array, comparing the transcrip- 
tome of AGS cells in the two culture conditions. Among    
the 340 differentially expressed transcripts, a 1.7-fold 
upregulation of MEX3A was observed in the 3D condition 
(Figure 2A and Supplementary Table S2). Additionally, 
functional annotation analysis showed alterations related     
to fundamental cellular processes like proliferation, differ- 
entiation  and  survival,  namely  an  increase  in  cell  cycle 
elements, Notch and Wnt pathways and a decrease in   
MAPK and Jak-STAT signalling in  the 3D model       
(Figure 2B). An increase in RhoGTPases and integrin 
signalling was also registered, supporting the occurrence     
of increased cell-matrix interactions. Changes in metabolic 
patterns were evident by an increase in amino acid biosyn- 
thesis (Figure 2B). MEX3A is one of the human ortho- 
logues of MEX-3, an RBP with translational inhibitory 
function known to target the CDX orthologue pal-1 during  
C. elegans embryonic development. A novel inter-        
action between human MEX3A and CDX2 in a gastro- 
intestinal context could constitute a plausible explanation   
for the reduction of CDX2 protein levels observed in 3D 
culture. Accordingly, MEX3A expression was validated by 
qPCR (Figure 2C). 
 
MEX3A overexpression leads to CDX2 downregulation 
in AGS cells 
To deﬁne whether CDX2 expression is regulated by 
MEX3A, AGS cells cultured in standard conditions were 
transiently transfected with a myc-tagged MEX3A expres- 
sion vector and collected 24 and 48 h later. We showed that 
the myc-tagged MEX3A fusion protein was detectable on 
transfection and accompanied by a 77 and 64% decrease in 
CDX2 protein  expression,  respectively  (Figure  3A). In 
contrast, CDX2 mRNA expression did not change        
(Figure 3B). This result was conﬁrmed in AGS cells      
stably transfected with the myc-tagged MEX3A construct   
up until 96 h of culture (Figure 3C and D). 
 
 
 
 
Figure 2. Transcriptome proﬁling of 2D and 3D AGS cultures. (A) Microarray heat map displaying differentially expressed transcripts (P < 0.01,                   
fold change > 1.5). Values obtained for MEX3A are highlighted. (B) Functional annotation analysis depicting the preponderance of differentially          
expressed genes in terms of signaling networks (P < 0.05, fold change > 1.5). (C) qPCR validation of MEX3A expression. Values for MEX3A mRNA 
expression in 2D culture were referred to as 1. 
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Figure 3. CDX2 regulation by MEX3A in AGS cells. (A) Western blot of transient transfections with a myc-tagged MEX3A expression vector.                         
(B) qPCR of CDX2 and MEX3A mRNA expression in the previous samples. The value for CDX2 mRNA expression in the empty vector transfected                
cells at 24 h was referred to as 1. (C) Immunoﬂuorescence for MEX3A and CDX2 in MEX3A stably transfected cells at 48 h culture (original       
magniﬁcation, x400; scale bar 20 µm). (D) Western blot of MEX3A and CDX2 expression in stably transfected cells at different time points. 
 
 
 
It was previously published that MEX3A and MEX3B 
were novel components of P bodies (28,29), discrete cyto- 
solic foci characterized in yeast and mammals as centres for 
translational silencing and mRNA decay (41). In our    
setting, on MEX3A-induced CDX2 protein decrease, we 
observed a speciﬁc subcellular localization of MEX3A in P 
bodies, as confocal microscopy analysis revealed a partial 
overlap between myc-tag staining and two known P body 
components, the human mRNA-decapping enzyme 1A 
(DCP1A) and the human enhancer of mRNA-decapping 
protein 4 (EDC4) (Supplementary Figure S1). Together, 
these results demonstrate that MEX3A has the ability to 
regulate CDX2 expression at the post-transcriptional level, 
probably by interplay with P bodies. 
 
MEX3A interacts with a MRE present in CDX2 3`UTR 
 
A bioinformatics search conducted throughout the CDX2 
3`UTR led to the identiﬁcation of the MEX-3 degenerate 
consensus   binding   sequence   (36).  The   MRE  present  in 
CDX2 mRNA was deﬁned as a bipartite element that   
consists of AGAG and UUUA motifs separated by two 
Uracil bases (Figure 4A). To assess whether MEX3A 
associates with CDX2 3`UTR, we preserved RNA–     
protein interactions by ultraviolet covalent linkage in      
AGS cells transiently transfected with the MEX3A expres-                                  
sion vector and performed an RNA-immunoprecipitation 
(RIP) assay. We found a signiﬁcant enrichment in CDX2 
mRNA recovered with the anti-myc antibody compared   
with control IgG (Figure 4B). On the contrary, no enrich- 
ment for GAPDH mRNA was observed (Figure 4B). 
Likewise, no enrichment for TBP mRNA and 18S          
rRNA was detected (data not shown). Next, we asked 
whether MEX3A binds speciﬁcally to the MRE present 
within the CDX2 3`UTR. To address this question, Rluc 
expression vectors containing the wild-type CDX2 3`UTR 
(pRLCDX2) or the CDX2 3`UTR with a mutated MRE 
(pRL∆CDX2) were used in an RIP assay as before      
(Figure   4C).   A    complete    loss    in    MEX3A    binding 
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Figure 4. Mechanistics of MEX3A interaction with CDX2 mRNA in AGS cells. (A) Terminal sequence of CDX2 mRNA, with the predicted MRE                   
in the 3`UTR highlighted in bold and underlined. (B) qPCR showing CDX2 and GAPDH mRNAs immunoprecipitated with myc-tag antibody in             
MEX3A transfected cells (*P = 0.018). The values for CDX2 and GAPDH mRNA levels in the IgG sample were referred to as 1. (C) Schematic     
representation of pRL constructs. (D) qPCR showing Rluc mRNA immunoprecipitated with myc-tag antibody for pRLCDX2 transfection                         
(****P < 0.0001). Values for Rluc mRNA expression in IgG samples were referred to as 1. (E) Luciferase activity assay for the different pRL              
constructs (**P = 0.006 for pRLControl/pRLCDX2 and *P = 0.036 for pRLCDX2/pRL∆CDX2). The values obtained for luciferase expression in                   
the pRLControl co-transfected cells were referred to as 1. 
 
 
 
capacity was detected when the MRE was mutated, as 
observed by comparing the levels of Rluc mRNA re-   
covered with anti-myc antibody between the pRLCDX2    
and pRL∆CDX2 transfected cells (Figure 4D).    
Additionally, luciferase activity assays proved that the 
construct with the mutated MRE was insensitive to    
MEX3A function, as a signiﬁcant reduction in Renilla ex- 
pression was only detected with the pRLCDX2 transfec- tion 
(Figure 4E). We conclude that MEX3A is able to interact 
with CDX2 mRNA and that the major determin-                 
ant for this interaction is a putative MRE located in the 
transcript 3`UTR. 
 
Intestinal phenotype of Caco-2 cells is affected by 
modulating MEX3A levels 
To assess the functional consequences of the previous ob- 
servations and conﬁrm that they were cell-type independ- 
ent, we studied CDX2 regulation by MEX3A in another 
model. Caco-2 cell line was chosen for its ability to spon- 
taneously differentiate into an enterocytic-like phenotype    
on reaching conﬂuence, which has turned it into the most 
widely  used  system to study  intestinal cell maturation  (42). 
Furthermore, this process was previously shown to be 
accompanied by an increase in CDX2 protein expression 
that, in some established Caco-2 clones, is not explained     
by higher transcriptional levels (20). First, we evaluated     
the timing of CDX2 and MEX3A expression in Caco-2, 
harvesting cells at pre-conﬂuence (day -2), conﬂuence      
(day 0) and post-conﬂuence (day 2–8) time points.   
Consistent with previous reports, CDX2 protein expres-    
sion progressively increased starting from conﬂuence and 
during differentiation (Supplementary Figure S2A). This 
trend was also veriﬁed at the mRNA level, though not to    
the same extent (Supplementary Figure S2B). By contrast, 
MEX3A mRNA expression varied in a complementary 
manner to that of  CDX2,  with a decreased  expression 
associated to more differentiated cells (Supplementary   
Figure S2B), although a protein decrease was only        
visible at day 8 (Supplementary Figure S2A). We inhibited 
endogenous MEX3A using siRNA and observed that     
CDX2 protein started to be highly expressed at earlier                 
time points in cells with downregulated MEX3A expres-                         
sion (Figure 5A). Paradoxically, this effect was reverted   
from conﬂuence onwards,  with  lower  CDX2  protein levels 
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detected at later time points in cells with MEX3A inhib-   
ition (Figure 5A). To evaluate whether this result was 
dependent on MEX3A activity or due to transcriptional 
regulation, CDX2 mRNA expression was assessed. As 
expected, CDX2 mRNA levels were not altered in the       
pre-conﬂuence time points but were downregulated from 
conﬂuence onwards (Figure 5B), suggesting that after con- 
ﬂuence, other MEX3A regulatory functions indirectly 
interfere with endogenous CDX2 levels. 
It is known that Caco-2 cells acquire expression of 
different intestinal columnar lineage markers on differenti- 
ation, such as Villin. To determine the effect of MEX3A 
overexpression in intestinal differentiation, we generated a 
Caco-2 cell line stably transfected with the myc-tagged 
MEX3A construct. Expression of the myc-tag was con- 
ﬁrmed in different conﬂuence states, and a concomitant 
reduction in CDX2 protein levels was observed            
(Figure 5C). Furthermore, we detected decreased Villin 
expression  in  MEX3A  overexpressing  cells  (Figure 5C). 
As differentiation and growth arrest are spatially and tem- 
porally related events in the intestinal epithelium, we   
studied the expression of cyclin D1, a positive regulator       
of proliferation required for cell cycle G1/S transition. 
Sustained levels of cyclin D1 were detected in MEX3A 
overexpressing cells in latter time points, when the       
culture is normally already less proliferative, as observed    
by the striking decrease of cyclin D1 in mock cells      
(Figure 5C). To ascertain the cell cycle distribution       
related to MEX3A overexpression, we transiently trans- 
fected near-conﬂuent Caco-2 cells with the myc-tagged 
MEX3A construct and performed DNA content analysis     
by ﬂow cytometry. Measurements indicated that cells 
overexpressing MEX3A possess a different cell cycle    
proﬁle (Figure 5D), with a reduced  G0/G1  population      
(32 against 49% in the empty transfected cells) and an 
increased S phase population (41 against 30% in the      
empty transfected cells). Given the observed alterations       
in    differentiation    and    proliferation    parameters,   we 
 
 
 
 
Figure 5. MEX3A modulation of intestinal phenotype in Caco-2 cells. (A) Western blot of MEX3A inhibition with transfection of siRNAs per-                
formed at day -3 and day -1. (B) qPCR of CDX2 mRNA expression in the same samples. The value for CDX2 at day -2 for the siControl sample                     
was referred to as 1. (C) Western blot of MEX3A stably transfected cells at different conﬂuences for differentiation and proliferation markers.                        
(D) Flow cytometry analysis of MEX3A transiently transfected cells. Dot plots depicting negative control (secondary antibody only) and                             
FITC-conjugated MEX3A expression levels are shown on top. DNA content histograms showing population percentages for the different cell                      
cycle phases of the empty vector transfected cells and MEX3A-transfected cells (gate MEX3A exogenous) are shown below (*P = 0.03 for G0/                       
G1 phase and *P = 0.05 for S phase). 
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Figure 6. Expression proﬁles of intestinal stem cell markers in Caco-2 cells. (A) qPCR of LGR5 mRNA expression in mock and MEX3A             
overexpressing cells. The value for LGR5 at day -3 for the mock sample was referred to as 1. (B) qPCR of BMI1 mRNA expression in the                             
same samples. The value for BMI1 at day -3 for the mock sample was referred to as 1. (C) Western blot analysis of MSI1 expression in the same             
samples and in Caco-2 parental cell line with CDX2 inhibition by siRNAs at the conﬂuence time point. 
 
 
sought to determine whether MEX3A overexpressing cells 
possessed intestinal ‘progenitor or stem-like’ features. 
Assessment of expression of well-established intestinal    
stem cell markers (43–46) revealed that these cells show 
overall increased levels of LGR5, BMI1 and MSI1       
(Figure 6), whereas OLFM4 basal expression was barely 
detectable and did not change (data not shown).    
Importantly, this seems to be independent of CDX2, as 
siRNA-mediated CDX2 downregulation did not repro-    
duce the increase in MSI1 levels (Figure 6C). 
Caco-2 cells retain the ability to polarize and form a 
transporting epithelial monolayer in culture (42). This po-
larization process is intimately connected with the forma- 
tion of cell–cell contacts and adhesion. In standard culture 
conditions, Caco-2 cells overexpressing MEX3A showed 
alterations in the distribution of the tight junction marker  
ZO-1 compared with the mock cells (Figure 7A). We then 
used a 3D cell cyst assay (4) in matrigel to compare the 
phenotypic response of both cell lines. We observed that 
mock cells developed cyst-like structures in a few days,   
with ∼50% showing a well-deﬁned central lumen         
(Figure  7B–D).  In contrast, >80% of the MEX3A-
expressing cysts, in which CDX2 reduction and MEX3A 
increase was conﬁrmed, failed to elaborate such a lumen 
(Figure 7B–D). Additionally, we observed distinct      
patterns of E-cadherin and Phalloidin expression. We 
detected basolateral E-cadherin expression and accumula-
tion of ﬁlamentous-actin (F-actin) around the hollow     
lumen in the mock cysts (Figure 7D), and a reduced            
E-cadherin   expression   in   the   MEX3A-expressing  cysts, 
with F-actin appearing ubiquitously distributed (Figure     
7D). Thus, we show that the establishment of proper    
apical-basal identity is affected on MEX3A      
overexpression. 
 
MEX3A is differentially expressed in the crypt-villus unit 
 
To address MEX3A relevance in vivo, we analysed its 
presence in mouse normal intestine and compared it         
with CDX2 expression. We observed that MEX3A is 
expressed in small intestine and colon, exhibiting mainly      
a nuclear staining pattern. It shows a stronger expression     
in the lower portion of the crypt-villus unit in small intes- 
tine and reduced expression in the uppermost part of the 
colonic crypts (Figure 8). In the small intestine, CDX2 is 
expressed in the same cells as MEX3A except in the base    
of the crypts (Figure 8, insert) that exhibit mainly MEX3A 
protein. In colon, CDX2 is more expressed in the surface 
cells (Figure 8). These results suggest that MEX3A expres- 
sion might be important to deﬁne intestinal differentiation 
patterns. 
 
 
DISCUSSION 
 
In this study, we provide the ﬁrst demonstration that   
MEX3A represses CDX2 expression in the gastrointes-    
tinal context, putatively as a translational repressor, with 
direct implications in intestinal differentiation, polarity      
and stemness features, key mechanisms for tissue homeo- 
stasis that are frequently altered in pathological conditions 
and inextricably linked with cancer. 
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Figure 7. Polarity alterations induced by MEX3A in Caco-2 cells. (A) Immunoﬂuorescence showing ZO-1 expression in Caco-2 mock and MEX3A          
stably transfected cell lines at day -2 of culture (original magniﬁcation, x400). (B) Morphology of Caco-2 mock and MEX3A cysts in bright ﬁeld       
microscopy during 3D culture (original magniﬁcation, x100) and CDX2/MEX3A expression (original magniﬁcation, x630). (C) Quantiﬁcation of                
cysts with lumen or no lumen at culture day 8. (D) Expression of E-cadherin and Phalloidin staining in Caco-2 cysts (original magniﬁcation, x630;                   
all scale bars 20 µm). 
 
 
 
3D cell culture systems have been shown to enable 
physiological and functional differentiation of several epi- 
thelial cell types (47,48), constituting a promising alterna- 
tive to overcome standard cell culture limitations. 
Accordingly, our transcriptomic analysis performed on a    
3D model of AGS cells, which have a signiﬁcant level of 
endogenous CDX2 responsive to different molecular    
stimuli (13–15), allowed us to disclose MEX3A as a mo- 
lecular player involved in the regulation of CDX2 transla- 
tion. The array presented an increased MEX3A expression   
in 3D  culture  and  no  alteration  in  the  levels  of  the other 
MEX3 family members. We further demonstrated that 
MEX3A overexpression leads to marked CDX2 protein 
decrease in two cell lines. We tried to overcome the limi- 
tation of using overexpression systems by using two dif- 
ferent cell lines that were both transiently and stably 
transfected with a MEX3A plasmid, which gave concord-  
ant results. In addition, CDX2 negative regulation by 
MEX3A was conﬁrmed in a more physiological context 
using a siRNA approach towards endogenous MEX3A in 
Caco-2 cells. We proved that MEX3A is able to interact   
with  CDX2  mRNA  through   a   canonical  MRE  present 
 
 
CHAPTER 3.  CDX2 POST-TRANSCRIPTIONAL REGULATION BY THE RNA-BINDING PROTEIN MEX3A 
  
3996   Nucleic Acids Research, 2013, Vol. 41, No. 7 
 
 
 
Figure  8.  Expression patterns of MEX3A and CDX2 in mouse normal intestine. Representative immunoﬂuorescence data for MEX3A and CDX2 in            
small intestine and colon are shown (original magniﬁcation, x200; scale bars 50 µm; insert original magniﬁcation, x400). 
 
 
 
in the 3´UTR. This sequence, which we now show to be 
functionally relevant in humans, seems to be the single 
determinant of MEX3A binding, independently of the 
upstream 5`coding region. In fact, bioinformatics        
analysis shows that the degenerate MRE motif has been 
evolutionarily conserved in different CDX2 homologues 
(Supplementary   Figure   S3),    namely    in    chimpanzee, 
mouse, rat, zebraﬁsh, fruit ﬂy and frog, suggesting that 
MEX3A is critical for CDX2 regulation. 
Endogenously,  MEX3A  was  mainly  localized  in  the 
nuclear  compartment  of  intestinal  epithelial  cells,  both 
in vitro and in vivo. This result is crucial to show that            
a biological background for the regulation of CDX2 by 
MEX3A exists. In  this  regard,  a variant form of MEX3D 
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called TINO, which has been shown to negatively regulate 
BCL-2 expression by transcript destabilization, is also pre- 
dominantly localized in the  nuclei  of  HeLa  cells  (33). 
On the other hand, MEX3A transfectants showed pre- 
dominant cytoplasmic staining. A  potential  problem 
could be antibody speciﬁcity; however, this was success- 
fully evaluated by transfection of siRNA duplexes directed 
against MEX3A (Supplementary Figure S4). Therefore, 
the differential localization in distinct expression 
backgrounds might be because a certain threshold in ex- 
pression levels has to be achieved for cytoplasmic trans- 
location to occur, given that MEX3 proteins are capable 
of performing nucleocytoplasmic shuttling (28). On the 
other hand, speciﬁc subcellular distribution might be 
related with protein phosphorylation, in accordance with 
published data describing MEX3 members as phospho- 
proteins (28,29). Whichever the case, this does not contra- 
dict post-transcriptional regulation, as it can be elicited at 
multiple points of the transcript lifespan, including       
pre-mRNA processing in the nucleus, export from the 
nucleus to the cytoplasm and subsequent coordinated 
trafﬁcking of the mature mRNA to the translation ma- 
chinery. It also remains to be fully clariﬁed the conse- 
quence of partial accumulation in P bodies, structures 
involved in processes of mRNA degradation, nonsense- 
mediated mRNA decay, translational repression and 
RNA-mediated gene silencing (49), although there are 
several RBPs with established roles in translational regu- 
lation known to colocalize with P bodies (50,51). 
We used the Caco-2 cell line model to modulate MEX3A 
expression and assess its phenotype. Surprisingly, MEX3A 
inhibition produced distinct effects over CDX2 levels de- 
pending on cellular conﬂuence. MEX3A might selectively 
regulate unique subsets of targets in different culture con- 
ditions. In agreement, it is known that transcriptomic and 
proteomic changes occur during the progression from the 
proliferative state to spontaneous differentiation of Caco-2 
cells. Conversely, MEX3A might have a dual role, acting 
both as a repressor or enhancer contingent on the cellular 
microenvironment, as observed for other RBPs, like HuR 
(52). It is possible that intricate associations of MEX3A 
with other molecular effectors, namely other proteins or 
microRNAs, determine divergent regulatory endings. 
MEX3A overexpression  in Caco-2  cells  resulted  in 
pronounced phenotypic alterations. CDX2 and Villin 
downregulation were indicative of a loss in intestinal dif- 
ferentiation, which was further conﬁrmed by the ﬂow 
cytometric proﬁle, showing reduced G0/G1 population, 
usually associated with less-differentiated cells. Another 
hallmark feature of MEX3A overexpression was the 
altered cellular polarization in standard culture, as well 
as the impaired ability to form polarized structures in the 
presence of matrigel. These effects may be mediated by 
CDX2, as this transcription factor was previously shown 
to regulate intestinal Villin through recruitment of the 
Brm-type SWI/SNF  complex to its promoter (53), and 
MEX3A-expressing cysts closely resemble the ones 
obtained with Caco-2 cells in which CDX2 suppression 
was achieved by  lentiviral short-hairpin RNA particles 
(4). It is, therefore, important to ascertain the biological 
setting where this regulation might be determinant, which 
is suggested by the predominant expression of MEX3A in 
the stem, transit-amplifying and migrating post-mitotic 
cells of the intestine. Although CDX2 protein can be 
detected in most of these cells, its level is lower in the 
crypts compared with the uppermost differentiated cells 
of the villi (2,19,20). A similar increasing bottom-up 
gradient has been described along the colonic gland axis 
in the distal colon epithelium. By contrast, in situ hybrid- 
ization revealed that CDX2 mRNA was homogeneously 
distributed along the entire crypt-villus axis (20). Given 
this CDX2 protein expression gradient, that we also 
show, and lack of correlation with mRNA, it is likely 
that MEX3A ﬁne-tunes CDX2 levels in vivo as well, in a 
transcription-independent manner, providing swift avail- 
ability of the protein to meet the physiological require- 
ments of the continuously renewed gut epithelium. 
Moreover, it has been shown  that intestinal  stem  cells 
cannot differentiate into any of the intestinal lineages in a 
background of Cdx2 ablation (54), revealing the need for 
tight CDX2 regulation as determinant to proper phenotype 
switching. Most interestingly, we observed higher expres- 
sion of  different intestinal  stem cell  markers when we 
overexpressed MEX3A in Caco-2, suggesting that this 
protein is associated with stem cell features. Our AGS 3D 
model also showed a signiﬁcant upregulation of OLFM4 
(Supplementary Table S2), previously identiﬁed as a 
marker for LGR5+ stem cells in human intestine (46), 
although this gene was not directly upregulated in Caco-2 
cells, which might be due to intrinsic properties of each cell 
line. Strengthening the hypothesis for a role of MEX3A in 
stem cell potential, a recent publication showed that 
MEX3A is part of the molecular signature of the LGR5+ 
intestinal stem cells, presenting a 1.64-fold increase in 
relation to daughter cells, along with MSI1, LGR5 and 
OLFM4 (55). Furthermore, our study reinforces the 
increasing knowledge that other regulatory mechanisms 
in addition to transcriptional ones have important func- 
tions in stem cells. Although we do not know yet how 
MEX3A relates with the intestinal stem cell phenotype, 
we hypothesize that MEX3A overexpression in itself, 
together with the induction of a lessened differentiated 
phenotype and polarity defects mediated by CDX2 
downregulation, might be critical to allow a permissive en- 
vironment for the appearance of stemness features. 
Furthermore, the MEX3A–CDX2 axis might be important 
during early embryogenesis where CDX2 is required for 
correct trophectoderm differentiation, while absent from 
the inner cell mass, in a process that requires tight regula- 
tion (56). Interestingly, the pattern of expression of the C. 
elegans orthologues of both proteins was found to be 
mutually exclusive in early stages of embryogenesis 
(24,27). Still, it remains to be assessed the relevance of 
MEX3A in multiple pathological contexts of the gastro- 
intestinal tract where differentiation  abnormalities 
directed by CDX2 are key events. 
In conclusion, we have identiﬁed a novel role for 
MEX3A protein in the regulation of intestinal differenti- 
ation, polarity and stemness features, partially mediated 
by the repression of CDX2. This is the ﬁrst description of 
a CDX2 regulatory mechanism based on its mRNA 
control  by  an  RBP,  having  a  signiﬁcant  impact  in 
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intestinal homeostasis and likely in gastrointestinal 
carcinogenesis. 
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Supplementary Figure S1. Subcellular localization of MEX3A in P bodies (A) 
Immunofluorescence of MEX3A stably transfected AGS cells for myc-tag and for 
endogenous DCP1A and EDC4 proteins. (B) Immunofluorescence of MEX3A stably 
transfected Caco-2 cells for myc-tag and endogenous DCP1A and EDC4 proteins. 
White arrow-heads point to different  sites of  co-localization (original magnification, 
x630; scale bars 20 µm). 
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Supplementary Figure S2. Study of the expression profile of endogenous MEX3A in 
Caco-2 cells. (A) Western blot of MEX3A and CDX2 expression during Caco-2 
differentiation. The time-point in which confluence is achieved is referred to as day 0 
(culture day 6). (B) qPCR of MEX3A and CDX2 mRNA expression during the same 
time-points. Values for CDX2 and MEX3A at day -2 were referred to as 1. 
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Pan troglodytes CDX2 - One predicted MRE in the 3`UTR 
bp Sequence 
1991 AGAGTTTTTA 
 
 
Mus musculus Cdx2 - Two predicted MREs in the CDS 
bp Sequence 
873  GGAGTTTCACTTTA 
1171 GGAGGGGTTTTA 
 
 
 
Rattus norvegicus Cdx2 - Three predicted MREs, one in the CDS and two in the 
3`UTR 
bp       Sequence 
1010 GGAGGGGTTTTA 
1228 TTAGATTTTTTTTTTA 
2027 GGAGCTTTA 
 
 
Danio rerio cdx1a - One predicted MRE in the 3`UTR 
bp Sequence 
1176 TGAGTTTA 
 
 
 
Xenopus laevis cdx2 - Seven predicted MREs in the 3`UTR 
bp Sequence 
1269 ATAGACTTTTA 
1640 TTAGATCCCTTCTA 
1860 GTAGCATTTTA 
2251 GTAGGCAGCCTTTA 
2355 GGAGACGTTTA 
2488 TGAGTGTTTTATA 
2546 GGAGGATATATTTA 
 
 
Drosophila melanogaster cad - Four predicted MREs in the 3´UTR 
bp Sequence 
2235 ATAGCCGCATATATA 
2251 AGAGTTTTAACGTTTA 
2298 GTAGTTAATATA 
2469 ATAGCTATTTA 
 
 
 
Supplementary Figure S3. Bioinformatics search for MREs in CDX2 homologues of 
several species. Different MRE sequences located in the coding sequence (CDS) or 
3`UTR of the transcripts are shown. 
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Supplementary Figure S4. Inhibition of  endogenous MEX3A in Caco-2 cells. (A) 
Immunofluorescence for endogenous MEX3A at different time-points, upon inhibition 
with specific siRNAs for 24h (original magnification, x400; scale bar 20 µm). (B) 
Corresponding western blot analysis of MEX3A downregulation. 
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GI malignancies remain a leading cause of morbidity worldwide, affecting 
almost four million individuals per year. This health burden has been intensively 
tackled during the last decades in the search for new approaches of prevention and 
management, and though slow, some progress has been achieved. A major 
advancement in understanding cancer aetiology is the recognition that although 
intrinsically genetic in origin, its heterogeneous nature stems from complex 
interactions between environmental and host factors. At the cellular level, this implies 
that cancer cells are not isolated entities solely defined by the linear accumulation 
of irreversible genetic alterations. Carcinogenesis is a rather dynamic process 
characterized by ongoing adaptations to the surrounding microenvironment.  
The homeobox transcription factor CDX2 is a master regulator of intestinal 
differentiation. Not surprisingly, CDX2 deregulation is associated with GI carcinogenic 
processes, including IM onset during gastric cancer development and CRC, though 
its role in the latter is not consensual. Since structural alterations in the CDX2 locus are 
rare, it has become evident that regulation must account for the major alterations 
reported in CDX2 levels in different pathological conditions and consequently, for 
maintaining its normal homeostatic balance. Henceforth, efforts have been 
concentrated in defining the regulatory mechanisms underlying CDX2 expression. 
Indeed, several transcriptional, post-transcriptional and post-translational 
mechanisms have been described to control CDX2, making this a highly complex 
and tightly organized regulatory system. 
With the objective of unveiling new molecular mechanisms of CDX2 regulation, 
we focused on the role of microenvironmental influences as a guiding line. In this 
regard, we have studied the effect of methylation at the CDX2 promoter level and 
of MEX3A protein over CDX2 expression, an RNA-binding factor uncovered in a cell-
matrix interaction model. The different parts of this work are now debated in distinct 
sections, being pointed out within each one future research avenues of interest. At 
the end, a general conclusion is provided, integrating all data from a molecular and 
evolutionary standpoint.  
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Our analysis focused on two classically defined CpG islands, identified in the 
5`proximal flanking region, and thus, more likely involved in CDX2 regulation given 
the transcription start site proximity. We initially chose a panel of gastric cancer cell 
lines displaying differential expression of CDX2 mRNA to validate a bisulfite-modified 
DNA sequencing protocol and establish possible correlations with the CDX2 gene 
methyl-pattern. The choice of strategy was based on the fact that methylation-
specific PCR uses different pairs of primers to specifically amplify methylated or 
unmethylated sequences, providing a semi-quantitative output that might not be 
representative of the whole CpG island, while sequencing of individual PCR 
amplicons with an unbiased primer pair generates extensive methylation maps at 
single-nucleotide resolution. Herewith, we were able to determine that promoter 
methylation status does not correlate with CDX2 expression levels, which has been 
confirmed in following studies (Varon et al. 2012; Zhang et al. 2013). This is in 
accordance with the CDX2 methylation frequency not showing any relationship to 
different clinicopathological characteristics, like tumour histological type or invasion 
(Yuasa et al. 2005), a fact at odds with the knowledge that gastric cancers retaining 
CDX2 expression are less aggressive and more differentiated (Liu et al. 2007a). 
Contradictory results have also been published in oesophageal tissues, with the 
presence of methylated and unmethylated alleles in cancer, and unmethylated in 
matched normal epithelia, despite no detectable mRNA or protein in the latter 
(Vaninetti et al. 2009).  
We were interested in assessing methylation in IM pre-malignant condition 
compared to the normal gastric mucosa. We noticed the upper CpG island was 
heavily methylated in all cell lines tested, consistent with a previous description 
(Kawai et al. 2005), and hence could not be discriminative. As a result, we limited the 
tissue analysis to the lower CpG island only. Analysis of normal colonic mucosa, IM 
foci and matched adjacent normal epithelium showed a methylation pattern 
deemed inconsistent with the CDX2 tissue-type expression. Hence, CDX2 expression 
in IM is not attributable to demethylation, but to transcriptional activation by other 
mechanisms. This lack of correlation has also been observed in stomachs from 
normal mice and IM cases from Cdx2-transgenic mice (Mutoh et al. 2009). 
Concerning the intestinal background, a recent report stated that CDX2 promoter 
hypermethylation is rare in CRC cases and cell lines (Salari et al. 2012). Therefore, it 
 75 
5.1  CDX2 REGULATION BY PROMOTER METHYLATION 
 
CHAPTER 5.  DISCUSSION AND CONCLUDING REMARKS 
seems CDX2 promoter methylation is not causative for its own levels in intestine 
either, and cannot account for the subset of CRCs presenting heterogeneous CDX2 
expression.  
Most studies, including our own, assumed that functionally relevant DNA 
methylation occurs in proximal promoter areas, but it is possible that other sites might 
have been neglected. In fact, bioinformatic analysis reveals that at least three 
additional CpG islands exist in more distal 5` intergenic locations, approximately 6kb, 
8kb and 11kb from the CDX2 transcriptional start site, the last two overlapping the 
neighbouring gene PRHOXNB. CpG shore methylation is an emerging concept that 
might also be worthwhile exploring in this context. These are regions of lower CpG 
density that lie in close proximity, but often not within, CpG islands. Notably, and at 
least for colon, most cancer-associated alterations in methylation were 
predominantly observed in these areas, rather than restricted to CpG islands (Irizarry 
et al. 2009). In principle, these putative methyl-sites should be responsive to inhibitors 
of DNA methyltransferase activity as well. Nevertheless, the broad range nature of 
this type of treatments is expected to generate indiscriminate effects on multiple 
targets, whose net balance might not reflect increased CDX2 transcription. Thus, 
methylation profile analysis of these alternative regions stands as a future research 
goal. Another key point to be considered is the role of chromatin state. Cell type-
specific chromatin organization enables differential access to and activity of 
regulatory elements and the manifestation of unique cellular phenotypes. Alterations 
in these signatures are a common feature of cancer initiation and development 
(Suvà et al. 2013). Active promoter regions include heightened nuclease sensitivity 
implying nucleosome depletion, and histone modifications associated with 
transcriptional activation, such as methylation of histone H3 at lysine 4 (H3K4me1 or 
H3K4me3) and histone H3 acetylated at lysine 27 (H3K27Ac). Quite the opposite, 
nucleosome compaction, methylation of histone H3 at lysine 9 (H3K9me2 or 
H3K9me3) and of histone H3 at lysine 27 (H3K27me3) are essentially repressive traits 
(Zhou et al. 2011). In this regard, chromatin changes associated with CDX1 and CDX2 
expression were only described in one publication and in colon cancer cell lines (Lu 
et al. 2008). The in vivo pattern of these epigenetic marks, particularly in IM 
development, remains to be examined. 
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Given that previous reports described the role of epithelial-mesenchymal 
crosstalk as relevant for CDX2 expression, we established in vitro 3D culture models in 
order to study interactions between gastric epithelial cells and stromal elements that 
might regulate CDX2. These systems have now been applied with success to 
generate and maintain gastric and intestinal architecture in the form of organoids 
from single Lgr5+ stem cells (Sato et al. 2009; Barker et al. 2010). 
Our transcriptomic analysis comparing 3D with standard AGS cell culture 
revealed a remodeling of the gene expression program. Such adaptation was 
particularly noticeable by alterations in actin reorganization mediated by increased 
expression of GTPases of the Rho family, like ARHGEF9, which acts as a guanine 
nucleotide exchange factor for the polarity-related protein CDC42. An increase in 
COL4A5 and LAMB1 transcripts, for example, was also observed, which encode for 
type IV collagen and laminin, respectively, components of the basal lamina that has 
been shown to be primarily a product of epithelial cells, pointing towards an 
inductive feedback loop between the matrix and epithelial cells. Interestingly, we 
noticed a significant increase in cell cycle related elements, for instance in SGOL1, 
which encodes a protein that shields the cohesin complex from cleavage and is 
crucial for faithful chromosome segregation during mitosis and meiosis (Kahyo et al. 
2011); ERCC6L, a DNA helicase that is essential for maintenance of genome integrity 
(Baumann et al. 2007); and the polymerase POLD1, which functions in DNA 
replication/repair and whose mutations affecting the proofreading domains have 
recently been shown to increase the risk for colorectal carcinoma (Palles et al. 2013). 
Transcripts encoding inflammatory response factors, like chemokine ligands, 
interferons and interleukins, were all downregulated. Furthermore, an increase in 
Notch1, DLL1, and FZD1 was detected. Combinatorial control between these Notch 
and Wnt pathway members seems necessary to maintain intestinal stem cells (Fre et 
al. 2009). In line, the array showed a 60-fold increase in the expression of OLFM4, a 
specific marker of Lgr5+ intestinal stem cells (van der Flier et al. 2009).  
The previous results, together with the decreased CDX2 expression suggest that 
our AGS 3D cells resemble undifferentiated intestinal cells. Since AGS was first 
established from an intestinal-type gastric adenocarcinoma, we speculate that a 
partial reversion of the malignant towards an intestinal phenotype might occur under 
a physiologically more relevant microenvironment, reminiscent of what has been 
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observed in a mammary model (Weaver et al. 1997). The full potential of this model 
thus remains to be explored, as it might provide additional insights on factors 
involved in the regulation of intestinal differentiation.  
 
 
 
 
 
  
Through microarray analysis to dissect the transcriptional regulatory circuitry of 
AGS cells in culture with an extracellular matrix, and further supported by an 
evolutionary link, we identified and validated MEX3A as a CDX2 repressor. 
Considering the distinct experimental settings established, our interpretation is that 
MEX3A actively controls CDX2 expression during proliferative states, when fine-tuning 
of CDX2 at the transcript level seems more relevant to couple cell cycle arrest with 
the emergence of a differentiation program (Bai et al. 2003). In subsequent 
differentiated states, CDX2 expression has already been demonstrated to rely mostly 
in its protein stability (Boulanger et al. 2005). Hence, MEX3A might exhibit target 
specificity, and this hypothesis is favoured by the fact that it is still detected in the 
differentiated section of the crypt-villus unit, albeit weaker than in the lower portions, 
arguing for some activity in this compartment that might not be CDX2-oriented.  
Regarding the spatial compartmentalization in P bodies, we did not address if 
these are functionally relevant or if MEX3A effect on mRNA takes place as efficiently 
in the cytoplasm. Nevertheless, evolutionary comparative data supports this specific 
localization. C. elegans MEX-3 is involved in the correct segregation of large foci 
known as P granules to the final germline precursor (Draper et al. 1996; Schisa et al. 
2001; Jud et al. 2007).  P granules are membrane-free ribonucleoprotein cytoplasmic 
structures that primarily contain maternally expressed mRNAs alongside components 
shared with both P bodies and stress granules (Updike and Strome 2010). These three 
discrete microdomains are dynamically and reversibly induced in response to 
environmental signals. Thus, their nature seems to be in accordance with a function 
in maintaining or modifying certain RNA properties, delaying or even preventing the 
translational process. Inhibition of specific P body components through an RNAi 
strategy will help to shed light over MEX3A functional requirements. We showed that 
MEX3A interacts with CDX2 mRNA through a canonical MRE present in the 3`UTR. This 
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does not exclude the possibility of MEX3A recognizing either different variations of 
the degenerate sequence described for MEX-3 binding in C. elegans (Pagano et al. 
2009) or even other unknown sequences; however, it provides an anchor point to 
search for new targets. We have not assessed if the interaction is direct or mediated 
by another RBP that complexes with MEX3A, either through its RING domain or even 
through the KH domains, as these have also been shown to mediate protein 
oligomerization in some instances (Chen et al. 1997). RNA electrophoretic mobility 
gel shift assays with a probe containing the CDX2 3`UTR MRE sequence together 
with a MEX3A recombinant protein will provide a definitive answer concerning this 
issue. Another aspect that was not advanced is MEX3A own sequence and/or 
structural interaction determinants. MEX-3 proteins possess type I KH domains, which 
consist of three-stranded antiparallel β-sheets, oriented against three α-helices. The 
stable β-α-α-β-β-α conformation exposes a  flexible  loop   between   the   first  two  
helices, occupied by semi-conserved positively charged residues in a Gly-X-X-Gly 
motif (Valverde et al. 2008). Even though the total number of solved structures with 
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KH domains bound to cognate nucleic acid ligands is small, it seems this 
tetrapeptide is the putative RNA recognition surface. Data on the MEX3D second KH 
domain structure is available (Protein Data Bank entry 2dgrA), and since it shares 76% 
sequence identity with the corresponding MEX3A domain, the former can be used 
as template to model the second, providing insights into the possible docking 
process with target mRNAs (Figure 1). The KH domains role awaits experimental 
validation through the use of site-directed mutagenesis to introduce mutations in the 
conserved tetrapeptide and assess binding activity over CDX2 mRNA as readout.  
Most known examples of RBP action include proteins that repress translation,           
and under most circumstances initiation is the rate-limiting step, whose complexity                  
and importance are underscored by the fact that it is assisted by more 
than 25 polypeptides, while only a limited set of factors are dedicated for 
elongation and termination (Gebauer and Hentze 2004). During initiation, the 
scaffold factor Eukaryotic initiation factor (eIF)4G interacts both with the cap-binding 
factor eIF4E and the poly(A) binding protein (PABP), which is in turn bound to the 
poly(A) tail, resulting in mRNA pseudo-circularization (Wells et al. 1998). This mRNA 
closed-loop arrangement thus provides a physical framework for the action of 3`UTR 
effectors on translation initiation at the 5`end. Drosophila Bicoid (Bcd), for instance, 
binds to the 3`UTR of cad mRNA and recruits an elF4E-homologous protein (4EHP) to 
the cap structure, inhibiting translation because of its low affinity for eIF4G (Cho et al. 
2005) [Figure 2A]. Other RBPs recruit factors that mimic eIF4G and compete with it for 
eIF4E-binding. Such is the case of Xenopus cytoplasmic polyadenylation element 
binding protein (CPEB), which binds the 3`UTR of cyclin B1 mRNA and recruits the 
eIF4E-binding protein (4E-BP) Maskin to repress translation (Stebbins-Boaz et al. 1999) 
[Figure 2B].  But  translation  can  also  be  controlled  at  late-initiation,  in  a  cap-
independent manner. During erythroid differentiation, hnRNPs K and E1 bind to the 
15-Lipoxygenase (ALOX15) mRNA 3`UTR and control translation by blocking the 60S 
large ribosomal subunit loading (Ostareck et al. 2001) [Figure 2C].  
Based upon our results, it is likely that MEX3A is specifically affecting translation 
of the CDX2 mRNA, by a mechanism similar to the ones described. An effect upon 
nuclear processing of the transcript is unlikely, as we have detected comparable 
levels of CDX2 mRNA in transient overexpression experiments. Therefore, MEX3A 
might recruit factors that bind eIF4E and block its interaction with eIF4G (Figure 2D, 
arrow 1), it might interact directly with eIF4E or eIF4E-like isoforms (Figure 2D. arrow 2), 
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and/or it might hinder ribosomal subunit loading into the mRNA (Figure 2D, arrow 3). 
It has been shown that the interaction between eIF4E and either eIF4G or the 4E-BPs 
involves the sequence motif YXXXXLΦ, where X is any amino acid and Φ is 
hydrophobic (Rhoads 2009). Interestingly, an YRVVGLV motif is conserved in the MEX-
3 family members. Although most RBPs target the initiation step of translation, some 
regulators have been recently reported to target the elongation step (Friend et al. 
2012). Likewise, MEX3A might act at this point, interfering with the activity of specific 
eukaryotic translation elongation factors, which ultimately might lead to ribosome 
stalling (Figure 2D, arrow 4). It is also possible that some of these mechanisms require 
MEX3A functional interplay with miRs to reinforce repression (Figure 2D, arrow 5), a 
hypothesis further strengthened by the fact that CDX2 is a target of specific miRs 
whose binding sites lie in close proximity to the MRE. Protein co- immunoprecipitation 
experiments against translation factors, together with ribosome-profiling 
assays to ascertain whether CDX2 mRNA co-fractionates with polysomes in the 
MEX3A-overexpressing cells, will allow us to unveil the translation step and 
mechanism underlying the MEX3A regulatory function.  
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When we initiated the study of the regulatory role of MEX3A over CDX2 
expression, the available information about the MEX-3 family members was limited. It 
was only recently that several publications have shed light on the different biological 
processes in which the mammalian members are involved.  
The MEX3A transcript was found to be upregulated in about 64% of gastric 
cancer tissues compared with matched adjacent non-cancerous tissues, arguing in 
favour of a role of MEX3A in gastric carcinogenesis (Jiang et al. 2012). It is possible 
that MEX3A is responsible for the decreased CDX2 expression observed in about half 
of the gastric cancer cases. Data collected from the Oncomine cancer microarray 
database (www.oncomine.com) provides preliminary evidence in support of this 
assumption, as an outlier analysis ranks MEX3A among the top 2% genes 
overexpressed in a subset of gastric adenocarcinomas among two independent 
datasets comprising a total of 243 cancer cases. On the other hand, it is unlikely 
that MEX3A altered levels are directly involved in de novo CDX2 expression 
associated with IM onset, as CDX2 mRNA is absent from the normal gastric mucosa, 
hampering any type of post-transcriptional regulatory mechanism. Nevertheless, it 
will be interesting to determine the expression pattern of MEX3A protein in normal 
epithelium, IM, dysplasia and cancer tissues to begin elucidating its role in the gastric 
carcinogenic process. Our results bring forward a possible role for MEX3A in 
colorectal carcinogenesis, not only through CDX2 regulation, but also through its 
association with loss of polarity and gain of stemness properties. MEX3A might directly 
contribute to the decreased CDX2 expression observed in a subset of colorectal 
carcinomas, particularly those with minimal differentiation. Furthermore, a prominent 
feature of differentiated and polarized simple epithelia is the presence of junctional 
complexes at the boundaries between neighboring cells. A modest increase in E-
cadherin expression (Lorentz et al. 1997) and enhanced E-cadherin trafficking 
activity to the membrane (Funakoshi et al. 2010) has been reported in CDX2-
overexpressing cell lines, leading to a mature morphogenesis, associated with 
increased adhesive potential. We have shown that expression of MEX3A is 
associated with decreased E-cadherin expression in 3D cysts, which might result from 
a direct translational repression by MEX3A or indirectly from MEX3A-induced CDX2 
suppression. Interestingly, the CDH1 transcript encoding E-cadherin harbors several 
MRE motifs in its 3`UTR.  On the other hand, it has been shown that LGR5+ crypt 
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intestinal stem cells are the cell of origin of adenomas (Barker et al. 2009) and that 
74-85% of CRCs express a Lgr5+ associated signature (Ziskin et al. 2013). These 
observations suggest that a stem cell/progenitor cell hierarchy is maintained in early 
stem-cell-derived adenomas and during cancer progression, which would lend 
support to the newly introduced cancer stem cell concept (Huang and Wicha 2008; 
Merlos-Suárez et al. 2011). We have shown an increase in intestinal stem cell markers 
expression, including LGR5, in MEX3A-overexpressing cells. Data extracted from 
Oncomine reveals an over 3-fold increase in MEX3A expression in two independent 
datasets comprising a total of 231 colorectal adenocarcinomas (Figure 3). 
Moreover, the RNA-binding QKI protein, the mammalian orthologue of GLD-1 and a 
key regulator of cell-cycle withdrawal and differentiation of the gastrointestinal 
epithelium, is downregulated in CRCs (Yang et al. 2010). Enticingly, GLD-1 is capable 
of repressing MEX-3 expression in C. elegans (Mootz et al. 2004). All these evidences 
favour a link between MEX3A and colorectal malignancy, which we will address in 
the near future.  
The interplay we uncovered between MEX3A and stem cell properties is an 
aspect that parallels the role of C. elegans MEX-3 in keeping distal germ cells 
totipotency (Ciosk et al. 2006). In the most distal end of the nematode gonad, which 
can be viewed as a stem cell niche where active division occurs, MEX-3 functions 
redundantly with the PUF family protein PUF-8 to prevent mitotic germ cells from 
terminally differentiating (Ariz et al. 2009). Since puf-8;mex-3 double mutant gonads 
maintain germ cell identity and differentiation capacity but have several mitotic 
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defects, germline-specific cell cycle regulators might constitute a potential group of 
PUF-8 and MEX-3 common targets. Other reports in different biological contexts 
secondarily reinforce this relationship. For example, it was shown that LIN28B inhibits 
the let-7 miR family and is capable of reprogramming hematopoietic progenitor cells 
from adult mice bone marrow, endowing them with the ability to mediate multi-
lineage reconstitution that resembles foetal lymphopoiesis (Yuan et al. 2012). A deep 
RNA-sequencing approach identified a specific global derepression of putative let-7 
target mRNAs that includes Mex3a. In addition, global gene expression profiles 
comparing the transition from quiescent to activated satellite muscle cells in 
response to injury show a global alteration in RBPs and miRs expression levels, 
including a decrease in Mex3a and Mex3b transcripts (Pallafacchina et al. 2010; Crist 
et al. 2012). RBPs might be critical to prevent uncontrolled growth and differentiation 
in any stem cell niche, be it embryonic or adult, where regulation of gene expression 
at the post-transcriptional level is a common theme (Sampath et al. 2008; Ghosh et 
al. 2009). Hence, it seems likely that MEX-3 proteins are important players in the 
reprogramming or maintenance of cells with multiple differentiation potentialities, by 
controlling expression of stem cell factors, suppressing differentiation, or both.  
 
 
 
 
 
  
MEX-3 regulates blastomere identity during C. elegans embryogenesis, ensuring 
translational control of pal-1 expression. But CDX2 is also an important mediator of 
trophectoderm (TE) cell fate specification in mammals. Given the high degree of 
homology between the MEX-3 family members, a role during mammalian 
embryogenesis might have been equally conserved.  
The first report of a putative mex-3 orthologue was on an invertebrate maternal 
transcript named posterior end mark 3 (pem-3), isolated from the ascidian Ciona 
savignyi (Satou 1999). The PEM-3 protein contains two KH domains which are 83% 
identical to the ones of C. elegans MEX-3 and an additional RING finger consensus 
sequence, but its function is unknown. As for the zygotic transcript, it was suggested 
to play a role in brain differentiation of the ascidian larvae. Drosophila Cad protein 
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plays a role in posterior patterning, accumulating in a posterior-to-anterior 
concentration gradient, even though cad mRNA is uniformly distributed in the 
syncytial embryo (Mlodzik et al. 1985). Interestingly, a MEX-3 orthologue is also 
present in Drosophila, however, it is not expressed at the blastoderm stage when the 
Cad gradient forms (Schoppmeier et al. 2009). It seems that, in this case, cad 
regulation has been taken over by Bcd, the primary determinant of anterior 
patterning (Driever and Nüsslein-Volhard 1988; Niessing et al. 2002). Surprisingly, the 
bcd gene possesses a limited phylogenetic distribution and has not been isolated 
from species other than Diptera (Brown et al. 2001). In the flour beetle Tribolium, a 
non-dipteran insect, it was observed that strong depletion of Tc-mex-3 led to severe 
phenotypic aberrations, ultimately resulting in complete deletion of the entire head 
(Schoppmeier et al. 2009). The functional similarity of MEX-3 in the nematode, 
ascidian and beetle embryos suggests that MEX-3 is a basic element of an ancestral 
fate-promoting mechanism that supports anterior patterning, at least in part by cad 
repression.  
As for mammalian embryonic development, one of the earliest molecular 
events observed during lineage determination is CDX2 expression in TE precursors 
(Beck et al. 1995). Lack of Cdx2 in homozygous-null mouse embryos is associated 
with failure to downregulate Oct4 and Nanog in outside cells, resulting in peri-
implantation lethality (Niwa et al. 2005; Strumpf et al. 2005). Currently, two opposing 
lines of thought exist concerning CDX2 role during embryogenesis. On one side, Cdx2 
is regarded as not being essential for initiation of TE formation, acting only later 
during maintenance of TE (Ralston and Rossant 2008; Wu et al. 2010). On the other 
hand, a mutually reinforcing relationship between cellular polarity and expression 
of CDX2 has been advocated, such that positioning of cells influence expression 
of Cdx2 and early CDX2 levels influence the proportion of blastomeres contributing 
to TE (Jedrusik et al. 2008; Jedrusik et al. 2010).  Although the exact position of CDX2 
in the lineage-determining hierarchy is not entirely clear, its tightly controlled spatio-
temporal expression raises the important question of what are the molecular 
mechanisms acting underneath. Cdx2 mRNA has been detected at low levels in 
oocytes, zygotes and in two- to eight-cell embryos (Wang et al. 2004b; Jedrusik et al. 
2010; Wu et al. 2010). While the major burst of zygotic genome activation occurs at 
the late two-cell stage, Cdx2 transcript levels only increase strikingly at the sixteen-
cell stage. Moreover, CDX2 protein is clearly detected in blastomeres nuclei at the 
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eight-cell stage, which precedes establishment of distinct cell populations (Ralston 
and Rossant 2008; Jedrusik et al. 2010). Since these cells will give rise to both the inner 
cell mass and TE, the corollary of this delay is that Cdx2 must be repressed during 
initial apolar divisions, and upon induction it must be silenced and maintained as 
cells are allocated to inside or outside positions, respectively. Transcriptional control 
in response to lineage segregation is an already established means of regulating 
Cdx2 (Nishioka et al. 2009), but it is not well understood how this is imposed in the first 
place.  
Asymmetric cell divisions produce daughter cells with distinct fates, and rely on 
the distinct segregation of key determinants, including localized mRNAs. 
Accordingly, it was reported that Cdx2 transcripts become preferentially localized 
apically at the late eight-cell stage and asymmetrically inherited during mouse 
development at the eight- to sixteen-cell stage transition (Jedrusik et al. 2008). This 
was not seen for transcripts encoding other cell commitment transcription factors, 
like Nanog. A compelling hypothesis is that MEX3A might contribute to the initial 
Cdx2 mRNA repression and possibly to its apical enrichment, recapitulating C. 
elegans MEX-3 effect over pal-1. This possibility is strengthened by a report showing 
that in mouse Cdx2 asymmetric localization depends on a minimal cis-element 
comprising the last 97 nucleotides of the transcript open reading frame (Skamagki et 
al. 2013), where we had already identified one MRE and another one close 
upstream. Assuming this scenario, MEX3A might be involved in the regulation of the 
Cdx2 transcript translation in an embryonic setting or even in its transport, as it was 
demonstrated that intact microtubules and actin cytoskeleton, together with the 
activity of motor proteins of the kinesin superfamily are a requirement for this 
asymmetric localization (Skamagki et al. 2013). Thus, MEX3 proteins might act as 
conserved components of the cell polarization pathway contributing to CDX2 
regulation during mammalian embryogenesis, thereby linking gene regulation and 
positional information.  
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With this work, we have advanced the knowledge on the molecular 
mechanisms of CDX2 regulation. On one hand, our results support the lack of 
evidence in favor of a role of methylation on de novo CDX2 expression in the 
gastritis-metaplasia-carcinoma sequence, contributing to solve an ambiguous topic 
in the field. On the other hand, we provide evidence of a new mechanism of CDX2 
post-transcriptional regulation mediated by the RNA-binding protein MEX3A. The 
relevance of MEX3A just started to be unraveled, but our data points towards its 
involvement in intestinal homeostasis and possibly gastrointestinal carcinogenesis, 
with effects in cellular polarity and stemness. In this regard, we will now ascertain the 
role of MEX3A by studying its expression in preneoplastic and neoplastic lesions, as 
well as its correlation with CDX2 and clinicopathological parameters. In parallel, we 
will establish a transgenic mouse model with conditional and inducible MEX3A 
expression in the villi compartment of the intestine, in order to assess the effects of 
ectopic MEX3A over the intestinal phenotype. This will be complemented by a 
transcriptome-wide analysis of MEX3A regulatory interactions. Overall, we expect to 
significantly contribute to the understanding of the impact of MEX3A post-
transcriptional control on gene expression, both in homeostasis and disease. 
Even considering MEX-3 well-described role in C. elegans embryonic 
development and maintenance of cell totipotency, it is remarkable to find such a 
marked degree of functional parallelism in higher organisms, a feature that one can 
predict to reflect the importance of this protein family. Consequently, it seems we 
have disclosed a case of evolutionary conservation that might have major 
implications for basic and clinical research.  
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Appendix 
 
ANTIBODIES
Antigen Application Description Dilution Source Commercial reference 
Actin WB Rabbit polyclonal 1:8000 Santa Cruz Biotechnology sc-1616-R
CDX2 IF and WB Mouse monoclonal IgG1 (Clone CDX2-88) 1:50 and 1:1000 Biogenex MU392A-UC
Cyclin D1 WB Rabbit monoclonal (Clone SP4) 1:500 Thermo Scientific RM-9104
DCP1A IF Rabbit polyclonal 1:500 Sigma Aldrich D5444
E-cadherin IF Mouse monoclonal IgG1 (Clone HECD-1) 1:300 Takara Biochemicals M106
EDC4 IF Rabbit polyclonal 1:400 Cell Signaling Technology 2548
F-actin IF Tetramethylrhodamine B isothiocyanate (TRITC)-conjugate of phalloidin 1:10000 Sigma Aldrich 77418
MEX3A IF and WB Rabbit polyclonal 1:600 and 1:1000 Sigma Aldrich PRS4869
MSI1 WB Rabbit polyclonal 1:1000 Millipore AB5977
c-Myc IF and WB Mouse monoclonal IgG1 (Clone 9E10) 1:600 and 1:1000 Clontech 631206
Villin WB Mouse monoclonal 1:3000 Kindly provided by Dr. Sylvie Robine, Institute Curie, Paris, France ―
ZO-1 IF Rabbit polyclonal 1:50 Invitrogen 61-7300
Secondary
Goat anti-Mouse IgG IF Alexa Fluor 488 or Alexa Fluor 594 conjugated 1:100 Invitrogen A-11001 or A-11005
Goat anti-Mouse IgG WB Horseradish peroxidase (HRP) conjugated 1:2000 Santa Cruz Biotechnology sc-2005
Goat anti-Rabbit IgG IF Alexa Fluor 488 or Alexa Fluor 594 conjugated 1:100 Invitrogen A-11008 or A-11012
Goat anti-Rabbit IgG WB Horseradish peroxidase (HRP) conjugated 1:2000 Santa Cruz Biotechnology sc-2004
PRIMER SEQUENCES (5`- 3`)
Bisulfite sequencing
CpG1 F: TTTTAGAAATGATAGGATGAAGG
R: ACCAAAAAACCTAAAACTAAAAA
CpG2.1 F: GTAGGTTAGAGGGAGGGAT
R: TCCTTATCCAAAAAATAACTCAC
CpG2.2 F: GAGTTATTTTTTGGATAAGGA
R: TAACCATTCCAATCCTCCC
CpG2.3 F: GGGAGGATTGGAATGGTTA
qPCR R: TTTACAACAACCCAAAAAC
18S F: CGCCGCTAGAGGTGAAATTC
R: CATTCTTGGCAAATGCTTTCG
BMI1 F: GTCTACATTCCTTCTGTAAAACG
R: CTTGGAGAGTTTTATCTGACC
CDX2 F: TTCACTACAGTCGCTACATCACCAT
R: TTGTTGATTTTCCTCTCCTTTGCT
GAPDH F: TCAAGGCTGAGAACGGGAAG
R: AGAGGGGGCAGAGATGATGA
LGR5 F: CAGCGTCTTCACCTCCTACCTA
R: CCTTGGGAATGTATGTCAGAGC
MEX3A F: CAAGCTCTGCGCTCTCTACAAA
R: GGCCTTAATCTTGCAGCCTTG
Rluc F: TGCAAGCAAATGAACGTGCTG
R: TCTAGCCACGGGCTCGATGT
Site-directed mutagenesis
pRL∆CDX2 vector* S: GTAACATCCAAGCCAGCCTTTTCCAAGCCTTCTGGATCC
AS:GGATCCAGAAGGCTTGGAAAAGGCTGGCTTGGATGTTAC
* Mutated nucleotides are in bold and underlined
Appendix A. List of antibodies and primers used in this study.
 
 
 
  
 
  
 
  
 
  
 
  
 
  
 
 
 
 
 
 
  
